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2. Summary 
Cutaneous leishmaniasis is a neglected tropical disease with a prevalence of roughly 12 million 
people worldwide.  It is caused by protozoan parasites of the genus Leishmania and transmitted 
by the bite of female sandflies of the subfamily Phelbotominae. Its clinical presentation is 
characterized by the development of an ulcerative lesion but can be highly variable. Neutrophils 
play an important role in the immunity against leishmaniasis. Upon infection they are massively 
recruited and infected. Furthermore, they can act as “Trojan Horses”, when apoptotic 
neutrophils that are phagocytized by macrophages silently transmit parasites into the latter. 
Here, we focused on specific roles of neutrophils in leishmaniasis. We show that an effective 
neutrophil response against Leishmania major (L. major) depends on Toll-like receptor 7 
(TLR7) signaling. The absence of this receptor in neutrophils leads to chronic leishmaniasis 
despite the development of a strong Th1 response in Tlr7-deficient mice. In contrast, activation 
of TLR7 at the time of infection leads to better disease control. In addition, we were able to 
show that the absence of TLR7 leads to a differentially regulated gene expression in L. major 
infected neutrophils. 
Furthermore, we demonstrate that the drug susceptibility phenotype of another Leishmania sp, 
Lesihamania (Viannia) panamensis (L. (V.) p.), modulates neutrophils main effector functions 
including neutrophil extracellular trap formation, reactive oxygen species production and the 
expression of extravasation and degranulation markers. In addition, drug resistant L. (V.) p. 
lines are more able to resist neutrophil mediated parasite killing.  
Taken together our data demonstrate the utmost importance of neutrophil response in the 
control of leishmaniasis and indicates the significance of continued investigation in this field to 
further improve patient care. 
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3. Résumé 
La leishmanisose cutanée est une maladie tropicale négligée qui a une prévalence mondiale 
d’environ 12 millions de personnes.  Elle est occasionnée par des parasites protozoaires du 
genre Leishmania et transmise par la piqûre de phlébotomes femelles. La manifestation clinique 
de la maladie est très variée. Souvent, elle est caractérisée par l’apparition d’une lésion cutanée 
ulcéreuse. Les neutrophiles jouent un rôle important dans la réponse immunitaire contre la 
leishmaniose. Ils sont massivement recrutés et infectés lors de la transmission du parasite. De 
plus, la phagocytose des neutrophiles infectés par des macrophages est une façon pour le 
parasite d’entrer les macrophages sans activer la réponse anti-inflammatoire connue comme 
mécanisme du «cheval de Troie». Dans la thèse présente, l’intérêt est mis sur certains rôles 
spécifiques des neutrophiles dans la leishmaniose. 
Premièrement, l’importance du signalement du récepteur de type Toll 7 (TLR7) dans la réponse 
des neutrophiles contre Leishmania major (L. major) a été démontrée. L’absence du TLR7 dans 
les neutrophiles cause une chronicisation de la leishmaniose. La stimulation du récepteur, au 
moment de l’infection avec L. major, résulte en un meilleur contrôle de la maladie.  Ceci se 
produit chez les souris déficientes en TLR7 en dépit du développement d’une réponse de type 
1 des cellules T auxiliaires, normalement protective. De plus, les neutrophiles infectés avec L. 
major ont montré des différences importantes dans l’expression génétique globale en l’absence 
de TLR7. Dans une deuxième partie, nous avons démontré l’implication du phénotype de la 
susceptibilité médicamenteuse de Leishmania (Viannia) panamensis dans la régulation des 
fonctions principales des neutrophiles. De plus, les parasites résistant aux médicaments ont été 
démontrés plus résistants à l’élimination par les neutrophiles. Ensemble, nos données 
démontrent l’importance d’une réponse immunitaire adéquate des neutrophiles pour le contrôle 
de la leishmaniose et indiquent l’importance de la poursuite des investigations dans ce domaine 
pour améliorer les soins aux patients. 
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4. Introduction 
4.1 The Immune System 
4.1.1 The History of Immunology 
The first recorded accounts of immunological concepts were documented around 2000 B.C. in 
the Babylonian epic of Gilgamesh. Even though people living in these times believed that 
diseases were brought upon them by deities as punishment of unfavorable behavior, they noted 
that people who survived a particular disease had a certain protection against it in the future. 
This observation was also made during the plague outbreak in Athens 430 B.C. as reported by 
the Greek historian Thucydidies1. Later, in 900 A.D. the Persian physician Abü Bakr 
Muhammad ibn Zakariyyā al-Rāzī described the concept of acquired immunity in the context 
of his research about smallpox and measles2. It has been reported that from around the year 
1000 on, people in China used crusts of pustules from smallpox victims as an inoculum in order 
to immunize people against this disease. In 1796, the English physician Edward Jenner 
inoculated James Phipps, the son of his gardener, with cowpox, based upon the observation that 
milkmaids that were infected with cowpox tended not to get infected with smallpox. After the 
inoculation with cowpox, James Phipps was exposed to smallpox against which he then was 
immune3. This was the beginning of the small pox vaccine that led to the eradication of 
smallpox in 19804. Jenner called this inoculum Vaccinia, derived from the Latin word “vacca” 
which means cow. 
In 1843 the French physician Gabriel Andral and the English physician William Addison 
described leukocytes for the first time5,6. The Russian biologist Ilya Ilyich Mechnikov published 
his “phagocyte theory” in 1883 which contained the first description of phagocytes and their 
role in host protection7. During the 20th century the field of immunology gained a lot of 
momentum, research efforts were intensified and a large series of discoveries were made, some 
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of which were awarded with the Nobel Prize in Medicine and Physiology and are listed in the 
table below (Figure 1). 
 
Figure 1: Noble Prizes awarded to immunologist in the 20th century (Doherty and 
Robertson, 2004) 
 
In the 21th century the field of immunology continues to thrive and a lot of outstanding 
discoveries are made. In 2002, the group of Jürg Tschopp first described the concept of  
inflammasome, an intracellular protein-complex that induces inflammation upon sensing of 
danger signals8. In 2004, a group of scientist including Arturo Zychlinky discovered that 
neutrophils can form extracellular traps made of chromatin and granule proteins. In the first 18 
years of this century the knowledge of immunology broadens while the fields of study become 
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more specific. In 2011 Bruce A. Beutler and Jules A. Hoffmann received the Nobel price in 
medicine and physiology for their discoveries concerning the activation of innate immunity, 
including Toll-like receptor signaling . The laboratory of Fabienne Tacchini-Cottier, in which 
this thesis was carried out, dedicates itself to research in immunity against Leishmania 
protozoan parasites. A lot of cutting-edge research was and is conducted in this laboratory, 
notably in the interaction of neutrophils with Leishmania9-15. 
 
4.1.2 The Immune System in Health and Disease 
The human body is constantly exposed to potential dangers present in the environment such as 
pathogens, toxins, foreign bodies and trauma but also to dangers arising from its own tissues 
and cells, i.e. cancer16. The immune system confers a certain protection against such dangers 
and consists of a complex interplay between organs, tissues, cells and molecules. It can be 
thought to be a system with various layers of defense: physical barriers such as skin or mucosae, 
chemical barriers such as stomach acid, the innate immune system and the adaptive immune 
system17. 
In order to function properly, the immune system has to discriminate between what is part of 
the healthy human body and what is not part of the healthy human body. A failure of the 
discrimination between “self” and “non-self” leads to the targeting of nonpathological cells and 
tissues by the immune system and which is known as autoimmunity and can lead to a wide 
variety of diseases, for example systemic lupus erythematosus, rheumatoid arthritis, multiple 
sclerosis or psoriasis18. 
 
4.1.3 Innate Immunity 
After the physical and chemical barriers of the immune system, innate immunity is the next line 
of defense against dangers. It consists of soluble components such as natural antibodies, 
proteins (e.g. C-reactive protein), the complement system and cellular components. The cellular 
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components are phagocytic cells such as neutrophils, antigen presenting cells such as dendritic 
cells and cytotoxic cells such as natural killer cells (NK-cells)19. 
The cellular components of the innate immune system can be divided into myeloid cells and 
lymphoid cells, depending on the form which common progenitor cells they arose. The 
lymphoid cells of the innate immune system include NK-cells and some subtypes of B- and T-
cells (e.g. NKT-cells, γδ-T-cells, B-1 B-cells)19,20. The myeloid cells consist of granulocytes, 
such as neutrophils, eosinophils and basophils, monocytes, macrophages and mast cells. 
Dendritic cells (DCs), important cellular components of the innate immune system, can arise 
from either the lymphoid or myeloid cell precursors21-23. 
 
4.1.3.1 Myeloid Cells 
Macrophages, whose name derives from the Greek words “makrós” meaning big and “phageín” 
meaning to eat, are cells that are specialized in phagocytosis, a process in which cells engulf 
and internalize foreign structures for the neutralization of potential dangers such as debris, 
pathogens or foreign bodies. Generally speaking there are two different types of macrophages. 
Tissue resident macrophages are nonmigratory cells that are found in specific tissues under 
physiological conditions (e.g. Kupffer cells in the liver, or microglia in the central nervous 
system) and are responsible for immune surveillance. Monocyte derived macrophages are 
recruited to the site of inflammation upon the sensing of chemotactic factors24. 
Monocytes are cells found in the blood circulation under homeostatic conditions. They make 
up about 10% of all circulating blood leukocytes with a half-life of about 3 days. Upon sensing 
of danger signals, monocytes are recruited to the site of infection and differentiate into either 
macrophages or DCs25.  
Dendritic cells are antigen presenting cells that can be divided into various subpopulations. The 
two main categories of DCs are classical DCs (cDCs) and plasmacytoid DCs (pDCs). pDCs are 
cells that are specialized in the production of type I interferons (IFN) upon activation. They are 
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found in lymphoid organs, the blood circulation and also in different tissues26. cDCs can then 
be further subdivided into lymphoid organ resident DCs and circulating tissue DCs. While 
lymphoid organ resident DCs have an immature phenotype and are not found outside the 
lymphoid organs, circulating DCs patrol between the different tissues in the body and the 
lymphoid organs, presenting antibodies to T-cells. Upon inflammation, another subset of cDCs, 
the inflammatory DCs, differentiates from monocytes and are also capable to present antigens 
to lymphocytes27. 
Mast cells are tissue resident effector cells that can be activated by different means. They are 
best known for their degranulation of several inflammatory and vasoactive mediators (e.g. 
Histamine, IL-6)28 after activation. This is the underlying mechanism of immediate onset 
hypersensitivity reactions29. They can be activated by IgE, the complex system, aggregated IgG, 
physical stimuli, cytokines and neuropeptides.  
Granulocytes play an important role in the rapid clearing of pathogens and in the regulation of 
immune responses. Their name derives from their characteristic granules in their cytoplasm that 
they can release upon activation. Under homeostatic conditions, they are found circulating in 
the bloodstream. Upon sensing of danger signals, they are readily recruited to the site of 
inflammation. There are three major types of granulocytes. Basophil granulocytes express IgE-
antibodies on the cell membrane and release high levels of interleukin-4 (IL-4) upon 
activation30. Eosinophil granulocytes are known to store a wide variety of cytokines in their 
granules and thus influence the immune response to a given stimuli. They furthermore play a 
role in immunity against pathogens by a variety of mechanisms including phagocytosis and 
reactive oxygen species (ROS) formation31. Neutrophil granulocytes are the most abundant 
leukocytes in the human blood circulation and are key players in immunity. 
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4.1.3.1.1 Neutrophils 
Neutrophils, also known as polymorphonuclears (PMN), have a characteristic lobulated nucleus 
and are important phagocytic cells of a variety of pathogens32. They have a diameter of about 
7-10 µm33, a life span of about 24 hours in the circulation34 which can be increased upon 
inflammation35. Neutropenia, a condition characterized by a low number of neutrophils in the 
blood circulation, that can be congenital or acquired, leads to an increased susceptibility to 
infection36,37. 
 
4.1.3.1.1.1 Development 
Most neutrophils originate from hematopoietic stem cells (HSC) in the bone marrow (BM) in 
a process called granulopoiesis. A healthy adult produces around 2x1011 neutrophils per day. 
Granulopoiesis is a multistep process in which various cytokine and transcription factors such 
as granulocyte colony stimulating factor (G-CSF) and the transcriptional suppressor growth 
factor independent 1 (Gfi1)38. Hematopoietic stem cells differentiate and proliferate into 
myeloblasts and then into promyelocytes. During this time the azurophilic granules of the 
neutrophils are formed. Then, they differentiate into myelocytes and further proliferate. 
Myelocytes are the last proliferating form in granulopoiesis that in a next step differentiate into 
metamyelocytes. During this step the specific granules of the neutrophil are formed. 
Metamyelocytes differentiate in band cells and the gelatinase granules are formed. Band cells 
are a first immature functional form in neutrophils that can be found in the blood circulation 
under inflammatory conditions. Under homeostatic conditions band cells form and turn into 
mature neutrophils which are then released into the blood circulation39. The last granule type 
called secretory vesicles are formed after the neutrophils exit the bone marrow40 (Figure 2). 
However, neutrophils can also differentiate from circulating hematopoietic stem and progenitor 
cells (HSPC) under inflammatory conditions41. It has been reported that Candida albicans 
drives HSPC to differentiate into mature neutrophils and macrophages42,43. Furthermore, HSPC 
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have been shown to traffic to Stahpylococcus aureus infected skin injuries and differentiate into 
mature neutrophils44.  
 
Figure 2: Schematic illustration of granulopoiesis (Yin et al., 2018) 
 
4.1.3.1.1.2 Migration and Extravasation  
Upon sensing of danger signals by the immune system, circulating neutrophils are quickly 
recruited to the site of inflammation by chemotactic factors such as IL-845. This migration 
involves neutrophils exiting the blood vessels by a process called extravasation. Upon the 
sensing of danger signals by tissue resident immune cells, chemotactic factors are released and 
the endothelium is activated in order to recruit leukocytes, which are in the beginning mostly 
neutrophils. The endothelium starts to express structures that can interact with neutrophil 
surface molecules. The neutrophils begin to roll along the blood vessel walls upon, which 
together with cytokines, a signaling cascade is activated which leads to the integrin mediated 
tight junction of neutrophils to the endothelium and subsequently to the migration through the 
endothelium to the inflammation site46.  
 
4.1.3.1.1.3 Neutrophil Effector Functions 
After migration to the site of inflammation, neutrophils exert different effector functions. 
Neutrophil possess three main effector strategies: neutrophil extracellular trap (NET) 
formation, phagocytosis and subsequent reactive oxygen species (ROS) production and 
degranulation of granules that contain microbicidal proteins47 (Figure 3). To kill engulfed 
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microbes, neutrophils produce different ROS which are synthesized by the enzymatic activity 
of NADPH-synthase48.  
 
Figure 3: Overview of neutrophil effector functions 
 
ROS are highly oxidative molecules that are microbicidal in a lot of contexts and are also 
involved in NET formation and signaling pathways49. During the process of degranulation, 
neutrophils granules can either fuse with pathogen containing phagosomes or be released into 
the extracellular space50. Three of the different classes of granules are formed during different 
stages of granulopoiesis: Azurophilic granules, specific granules and gelatinase granules. The 
fourth form of granules, secretory vesicles, are formed after the neutrophil exits the bone 
marrow40. All of them contain an arsenal of different microbicidal proteins46. 
Neutrophils are able to form NETs, fibrous structures that are composed of dsDNA coated with 
a variety of different microbicidal proteins. The process of NET formation is characterized by 
a cessation of cytoskeletal dynamics, cell membrane depolarization and subsequent expulsion 
of nuclear as well as in some cases mitochondrial DNA49. 
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4.1.3.1.1.4 Immune Modulatory Functions 
PMNs are not only short-lived effector cells but they are also involved in the shaping of the 
subsequent innate and adaptive immunity. In addition, they are important mediators of 
inflammatory processes. Upon activation, neutrophils are capable of secreting a great number 
of different cytokines and chemokines and they can interact with different types of leukocytes 
(Figure 3). Neutrophils have also been shown to be able to migrate to the draining lymph-node. 
Furthermore, it has been reported that neutrophils are able to attract T-cells to the site of 
inflammation, that they can modulate DC and B-cell function and that they are crucial in the 
modulation NK-cell function51,52. Finally, apoptotic neutrophils that are phagocytized by 
macrophages shape the functional phenotype of the latter53. 
 
Figure 4: Overview of cytokines and chemokines that can be produced by neutrophils 
(Tamassia et al., 2018) 
 
4.1.3.2 Pattern Recognition Receptors 
Leukocytes possess different classes of receptors that can detect a wide array of danger signals. 
The most important types of receptors are: The C-type lectin receptors that recognize glycan 
structures on pathogens54, the NOD-like receptors that sense intracellular danger signals and 
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the Toll like receptors that recognize pathogen associated molecular patterns (PAMPs) on the 
cell membrane and in the endosomal compartment55. PAMPs are structures or motifs that are 
invariant in pathogens of a given class and that are not present in the host, which makes them 
well suited for immune recognition56.   
 
4.1.3.2.1 Toll-Like Receptors 
Toll, a gene that was previously known to be involved in the embryonic development 
Drosophila melanogaster, was shown to be crucial in the antifungal immune response in these 
flies57. After that discovery, a series of similar receptors named Toll-like receptors (TLRs) that 
recognize pathogen associated structures were described in humans and other organisms58. 
TLRs are composed from a leucin-rich extracellular domain that recognizes pathogen 
associated proteins, glycans or nucleic acids and an intracellular domain that induces a signaling 
cascade over a Toll/interleukin-1 receptor (TIR)-domain upon receptor-activation. Signaling 
from the TIR-domains depends on different adaptor proteins like the myeloid differentiation 
primary-response protein 88 (MyD88). This protein is essential for all TLR signaling except in 
TLR3 and endosomal TLR4 which are able to signal through TIR-domain-containing adaptor 
protein inducing interferon-β (TRIF) dependent pathway59 (Figure 5). TLR signaling leads to 
the activation of transcription factor such as nuclear factor-κB (NF-κB) or interferon (IFN)-
regulatory factors (IRF) and eventually leads to the transcription of  pro-inflammatory cytokines 
and interferons60. The 10 human TLRs (TLR1-10) and the 12 murine TLRs (TLR1-9 and 
TLR11-13) can be subdivided into two groups. TLR1, TLR2, TLR 4, TLR5, TLR6 and TLR10 
are expressed on the cell membrane. TLR3, TLR4, TLR7, TLR8, TLR9, TLR 11, TLR12 and 
TLR13 are expressed on the endosomal membranes61. Phagocytized particles and pathogens 
like Leishmania are found within endosomes and can potentially induce TLR7 signaling as it 
was shown for RNA from group B streptococci in cDCs62.  
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Figure 5: Overview of TLR location, signaling pathways and potential ligands (O’Neill, 
2013) 
 
4.1.3.2.1.1 Toll-Like Receptor 7 
TLR7 is an endosomal Toll-like receptor that is known to recognize foreign single stranded 
RNA (ssRNA) and also responds to imidazoquinoline compounds such as imiquimod or 
resiquimod. It is closely related to TLR8 which in humans also recognizes ssRNA. TLR7 has 
been shown to have a high affinity to guanosine and uridine moieties in ssRNA63. In humans, 
TLR7 has been shown to be expressed on monocytes, macrophages DCs, B-cells, T-cells and 
NK-cells64-70, while in mice TLR7 has been shown to be expressed in DCs, macrophages, 
neutrophils, eosinophils and B-cells71,72. 
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4.1.3 Adaptive Immunity 
The adaptive immune response is the more specific line of defense of the immune system. There 
are two main branches of the adaptive immune system: the humoral response in which B-cells 
are the most important players and the cellular immune response which relies mainly on T-
cells. The adaptive immune system differs from the innate immune system in various aspects. 
While the innate immune system has receptors that recognize a fixed set of epitopes which are 
mostly conserved molecular patterns, the adaptive immune system can recognize a nearly 
infinite numbers of epitopes. This is because its receptors are not fixed in the genome but are 
composed of gene segments that are genetically recombined in a process called gene 
rearrangement. However, while the effector structures of the innate immune system are readily 
available, the adaptive immune system has to clonally expand the cells with the required 
specificity which makes it slower in the response. Finally, unlike the innate immune system, 
the adaptive immune system is able to establish immunological memory, the underlying 
mechanism of vaccines73.  
 
4.1.3.1 Humoral Immunity 
The hallmarks of humoral immunity are serum antibodies that are produced by long lived 
plasma cells that arise from B-cells. Antibodies interact with pathogens by interfering with the 
functions of their surface structures by increasing the phagocytosis of antibody marked 
structures and by activating the complement system. Antibodies can be categorized into 
different classes. IgD act mainly as B-cell receptor on resting B-cells. IgM is expressed on and 
secreted by B-cells in the early phases of an infection. IgG is secreted by plasma cells and are 
responsible for long term humoral immunity and can further be subdivided in their isotypes 
IgG1, IgG2, IgG3 and IgG4, which differ in their non-antigen-specific regions74. IgA and IgE 
are also produced by plasma cells. IgA is predominantly found in mucosal tissues while IgE is 
found in low concentration in the blood and is involved in atopic reactions75. Resting B-cells 
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are found in the lymph-node and are constantly exposed to a wide variety of antigens in the 
circulating lymph76. Upon binding of a B-cell receptor to its specific antigen and upon receiving 
costimulatory signals from T-helper cells, B-cells get activated. Subsequently, they proliferate 
and finally differentiate into different B-cell subsets such as plasma cells and memory B-cells77. 
Plasma cells are responsible for the maintenance of antibodies specific to the encountered 
antigen. Memory B-cells are resting cells that get reactivated upon reencounter of their specific 
antigen. Both cell types are very important in the maintenance of the antibody mediated 
immunity against already encountered antigens78.  
 
4.1.3.2 Cellular Adaptive Immune Response 
The main effector cells of cellular adaptive immunity are T-cells. Naïve T-cells are found in 
lymph nodes and express an antigen specific T-cell receptor. Antigen presenting cells such as 
dendritic cells present antigens to the T-cells on major histocompatibility complexes by 
interacting with its antigen specific T-cell receptor on T-cells. Besides antigen presentation, 
engagement of costimulatory molecules and cytokine signaling is necessary for T-cell 
activation79,80. There are different subtypes of T-cells such as T-helper cells (Th), cytotoxic T-
cells (CTL) or regulatory T-cells (Tregs). CTL express CD8 and are capable to kill targets that 
are recognized to be a threat to the organism. The direct cytotoxic effector functions of CTL 
are exerted either through the binding of the Fas ligand that is expressed on CTL with the Fas 
receptor on the target cell inducing apoptosis or through the action of perforins and granzymes 
which permeabilize the cell membrane of the target cell. Furthermore, these cells can secrete 
cytokines that are involved in the elimination of possible threats81. T-helper cells express CD4 
and have a wide variety of functions which are defined by the set of cytokines that they secret 
upon expression of distinct transcription factors. Several subtypes of T-helper (Th) cells have 
been characterized82. Tregs are immune suppressive cells that regulate the immune response. 
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They are important in preventing an excess of inflammation and preserve the immunological 
unresponsiveness to self-antigens83.  
 
4.1.3.2.1 T-helper Responses 
CD4+ T-helper cells can be categorized in different subsets: Th1, Th2, Tfh, Th17, Th22 and 
Th9. Th1 are known to play an important role in phagocyte activation and CTL proliferation 
and are known to be crucial in immunity against intracellular pathogens. The differentiation of 
naïve T-cells to Th1 cells is driven by the activation of the transcription factor T-bet through 
IL-12 and IFN-γ in a STAT-1 and STAT-4 dependent manner. Th1 cells are known to produce 
high levels of IFN-γ. Th2 cells are known to confer protection against extracellular pathogens 
such as helminths and to be involved in the pathogenesis of allergic diseases such as asthma or 
atopic dermatitis84. Th2 differentiation is driven by IL-4 which activates the transcription factor 
GATA3 through STAT-6. Tfh are important in the formation of germinal centers in secondary 
lymphoid organs where they provide T-cell help to B-cells. There play an important role in the 
induction of high affinity antibody production by B-cells and the formation of memory B-
cells85. Th17 cells are important for the clearance of extracellular pathogens through their ability 
to recruit and activate neutrophils. The differentiation of naïve Th cells into Th17 cells differs 
among species. In humans the differentiation is driven by TGF-β and IL-21 which leads to the 
activation of the transcription factor RORc. In mice TGF-β and IL-6 drive the Th differentiation 
through the transcription factor RORγt. In both species Th17 cells are known to produce high 
amounts of IL-17 but also IL-21 and IL-2286. Another Th subset was characterized that 
produces IL-22 without producing IL-17 and which was enriched in the human caecum. This 
subset is thought to play a role in mucosal immunity and is termed Th22. Naïve T-helper cells 
that are differentiated in presence of IL-4 and TGF- β were found to secrete IL-9 and were thus 
named Th9 cells. They are thought to be involved in autoimmunity and atopy87,88. 
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4.2 Leishmaniasis 
Leishmaniasis are a group of diseases caused by the protozoan parasites of the genus 
Leishmania. It is transmitted the bite of female phlebotomine sandflies of the genera 
Phlebotomus and Lutzomyia. 
 
4.2.1 The History of Leishmaniasis 
The first evidence for Leishmania was found in a sand fly conserved in 100 million old Burmese 
amber from the Hukawng valley. The Leishmania-like fossil species that was found in this sand 
fly, that also contained remnants of reptile blood, was assigned to a new genus and species and 
was called Paleoleishmania proterus89. In the Americas, another fossil species was found in a 
20-30 million old Dominican amber and was named Paleoleishmania neotropicum90. 
Leishmania donovani (L. donovani) mitochondrial DNA was found on four Egyptian mummies, 
dating from around 2000 B.C., that were found in a tomb in what was in the ancient city of 
Thebes91. In Peru, Leishmania infected macrophages in mummies from 800 B.C. were 
identified by immunohistochemistry92. In 930 A.D. the Persian physician Abubakr Muhammad 
ibn Zakariyya described cutaneous lesions reminiscent of leishmaniasis in patients of the 
Baghdad region93. In ceramics of the Moche culture, found in Peru and dating from the 5th 
century, depictions of facial conditions reminiscent of mucocutaneous leishmaniais (MCL) 
were found94. In 1571 the Spanish chronicler Pedro Pizzaro described cases of coca farmers in 
Peru who suffered from a disease that destroyed their nose and lips and was indicative of MCL. 
In 1756 the Scottish physician Alexander Russel made the first detailed description of the 
clinical picture of cutaneous leishmaniasis (CL) in patients from Aleppo95. In 1900, the Scottish 
physician and officer in the Royal Army Medical Corps William Boog Leishman described 
ovoid bodies in cells on smears taken form spleens of soldiers stationed in Dum Dum, India 
and that died from a disease causing splenomegaly. In 1903, he published his findings and 
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hypothesized that these ovoid bodies were degenerated trypanosomes and called the disease 
“Dum Dum fever”96. The Irish physician Charles Donovan published a paper about the finding 
of similar bodies in native Indian patients from Madras the same year 97. Also in the same year, 
the British physician Ronald Ross published two articles in which he concluded that the ovoid 
bodies were actually a novel form of protozoan parasite which he named Leishmania 
donovani98,99. Also in 1903, the U.S. pathologist James Homer Wright described organisms 
found in a CL lesion of an Armenian patient which would be eventually by named Leishmania 
tropica100. In 1973, Bray et al. proposed to classify L. tropica as two species based on the 
difference of size, Leishmania tropica and Leishmania major101. In the Americas, the first 
description of Leishmania parasites was done independently by the Brazilian physician 
Adolpho Carlos Lindenberg and the Italian physician Antonio Carini in skin lesions of patients 
from the State of Sao Paolo in 1909. In the beginning it was thought that the isolated parasites 
were identical to L. tropica, but in 1911 Brazilian physician Gaspar de Oliveira Vianna noted 
morphological differences from L. tropica in parasites isolated form a patient from São João de 
Além Paraiba and concluded that it was a different species which was named Leishmania 
braziliensis and would later, like other species found in the Americas, be part of the subgenus 
Viannia. In 1913 Leishmania peruviana was described for the first time. In 1930 the first cases 
of VL in the Americas were reported. In 1937, the Brazilian physicians Aristides Marques da 
Cunha and Evandro Serafim Lobo Chagas reported to have discovered a new species which 
they named Leishmania chagasi. However, more recent analysis techniques showed that L. 
chagasi and L. infantum were indistinguishable. The other Leishmania species that are known 
today were subsequently discovered from 1953 (Leishmania mexicana) until just recently in 
2015 (Leishmania waltoni)95, including L. martiniquensis that was first described in 1995 and 
was latter assigned to a third subgenus called Mundinia102. 
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4.2.2 Epidemiology 
Leishmaniasis is considered a highly neglected tropical disease which predominantly affects 
people of low socioeconomic status and is considered the second most deadly vector transmitted 
disease just after malaria103,104. It has been reported to be endemic in 98 countries and three 
territories. The worldwide incidence of CL is estimated to be 690’000 to 1’200’000 cases per 
year and that of VL is estimated to be 200’000 to 400’000 cases per year105. The cumulative 
worldwide prevalence is 12 million people106. There is an estimate that 20’000 to 50’000 people 
per year succumb due to leishmaniasis105,106.  
 
4.2.3 Clinical Manifestation and Diagnosis 
4.2.3.1 Cutaneous Leishmaniasis  
Leishmania parasites can cause a wide spectrum of cutaneous disease. In many cases, the 
infection with Leishmania remains clinically silent. In the clinically apparent cases, a papule 
appears after a sand fly bite that gradually develops and increases in size. It can develop into an 
ulcer, become a plaque or turn into a hyperkeratotic or wart-like lesion over the subsequent 
weeks and months107. This clinical picture is called localized cutaneous leishmaniasis (LCL) 
and varies widely in clinical appearance. Most cases of LCL are self-healing within two month 
to two years and results in cutaneous scaring and some degree of protection against the 
disease108. In some cases the parasites disseminate from the initial site of infection though the 
lymphatic system and create multiple pleomorphic nodules in two or more noncontiguous body 
areas, a condition called disseminated leishmaniasis (DL)109. In diffuse cutaneous leishmaniasis 
(DCL) the clinical picture is characterized by widespread multiple papulonodular or infiltrative 
cutaneous lesions110. In some other cases new papular lesions appear around healed LCL, a 
condition known as leishmaniasis recidivans (LR)111. Parasites can also disseminate to mucosal 
tissues which is known as mucocutaneous leishmaniasis (MCL). MCL begins often with an 
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erythema that develops into ulceration of the mucosal tissues of the oro-naso-pharyngeal area. 
It is associated with facial disfigurement and can end deadly due to secondary infections and 
the impairment of functions of the affected organs109.   
 
4.2.3.2 Visceral Leishmaniasis 
In visceral leishmaniasis (VL) Leishmania parasites infect secondary lymphoid organs and the 
liver. The clinically manifestations of VL can be hepatomegaly, splenomegaly, fever, anorexia 
and nocturnal hyperhidrosis and pallor. The patients often suffer from anemia, leukopenia, 
thrombocytopenia and hypergammaglobulinaemia. With disease progression patients suffer 
from pronounced cachexia, bleeding due to a decrease in coagulation capacity, secondary 
infections due to immune insufficiency and eventually succumb to the disease.  However, also 
clinically silent or oligosymptomatic disease progressions have been reported107,112.  
 
4.2.4 Leishmania 
There many different species of the genus Leishmania described, 19 of which are known to 
cause disease in humans95. The human pathological Leishmania spp. can be divided into three 
subgenera: Leishmania Leishmania, Leishmania Viannia and Leishmania Mundinia102. 
Moreover, there is the subgenus Sauroleishmania that is only infective to lizards. Species from 
the subgenus Leishmania Leishmania are found in tropical regions worldwide and can cause all 
the clinical forms of leishmaniasis. Leishmania Viannia are found only in the tropical regions 
of Latin America and can cause CL or MCL. Members of the subgenus Leishmania Mundinia 
can cause CL or VL and are found in Martinique and Thailand113,114 (Figure 6). Leishmania 
species are also categorized as Old World species and New World species depending on 
whether they are endemic in Europe, Asia and Africa or the Americas115.  
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Figure 6: Overview of the most important human pathological Leishmania species 
(Steverding, 2017) 
 
4.2.4.1 Leishmania Life Cycle 
The Leishmania life cycle is similar among the different Leishmania subgenera and species. 
Upon the bite of a host by a female sand fly, metacyclic promastigotes are regurgitated in the 
dermis together with sand fly saliva which contains neutrophils chemotactic factors116-120. This 
leads to a rapid recruitment of neutrophils to the site of infection9. Subsequently, neutrophils 
phagocytize the parasites or trap them in NETs14,121. In addition, neutrophils phagocytize other 
already infected cells which down-regulates neutrophil effector functions and is a mean of silent 
entry of Leishmania into neutrophils122. During and after the first wave of neutrophil 
recruitment, parasites will get taken up by macrophages which are their definitive host. This 
happens by the phagocytosis of apoptotic neutrophils that are infected with Leishmania by 
macrophages, a mechanism which is named “Trojan Horse” and again provides a mode of silent 
entry into the host cell123. Apoptotic neutrophil may also release parasites and the free parasites 
which can then get phagocytized by macrophages120. Inside the macrophages the parasites 
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reside within an acidic parasitophorus vacuoles (PV) where they transform due to the change 
in pH from their promastigote to their amastigote stage, i.e. their ovoid shaped replicative 
form124. Upon a blood-meal, another sandfly can take up the amastigotes which will transform 
into proliferating procyclic promastigotes and finally into infective metacyclic 
promastigotes125.   
 
4.2.4.2 Leishmania Vectors  
 
Figure 7: Overview of different vectors of leishmaniasis (Claborn, 2010) 
 
Over 500 sand-fly species have been described that belong to three genera: Phlebotomus, 
Sergentomyia and Lutzomyia. While Phlebotomus and Sergentomyia are found in the old world, 
Lutzomyia is found in the new world. Only a small proportion of the sand-fly species are known 
to be vectors of Leishmania in humans126 (Figure 7).  
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4.2.5. Treatment of leishmaniasis 
Even though there would be a need for efficient drugs against leishmaniasis there are only few 
compounds available, which have a lot of adverse effects. There is no efficient vaccine for 
humans on the market neither127. The most commonly used drugs against leishmaniasis are 
listed in the following table (Figure 8). 
 
Figure 8: Overview of different antileishmanial drugs (Bezerra de Menezes at al., 2015) 
 
4.2.5.1 Antimonny 
Pentavalent antimony (SbV) is the most ancient and the most commonly used compound in 
antileishmanial drug treatment. Currently, there are two different pentavalent antimony 
formulations available on the market: Sodium Stibogluconate (SSG) and meglumine 
antimoniate (MA). These compounds are usually used at dosage of 20mg/kg/day for 4 weeks. 
The use of SbV is associated with a wide variety of secondary adverse effects including cardio-
, hepato-, and renotoxicity128,129. Even though SbV has been the mainstay therapy against 
leishmaniasis for decades, its exact mode of action is still debated. Antimony is thought to kill 
Leishmania spp. by a variety of mechanisms including induction of cell death by a process 
involving DNA fragmentation130-132. Furthermore, antimony has been shown to inhibit the 
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enzymes trypanothione reductase and glutathione synthetase133 and to induce the efflux of 
antioxidant substances such as thiols and glutathione134,135, thereby inducing an increase of 
oxidative stress within the parasite. In recent years a marked increase in antimony treatment 
failure has been observed. SbV has already been eliminated as antileishmanial drug treatment 
against VL in India due to the resistance situation. Also in other countries there is an increasing 
number of reports about SbV resistance in leishmaniasis, for instance in Colombia 20% of 
Leishmania Viannia panamensis (L. (V.) p.) strains isolated from patients were resistant to 
meglumine antimony136. 
 
4.2.5.2 Miltefosine 
Miltefosine (MIL) was originally developed as antineoplastic drug but has since then been 
introduced as an antileishmanial drugs in various countries in the early 2000s. MIL is the first 
and thus far only antileishmanial drug that does not have to be administered parenterally but 
can be given per os. Usually, it is administered at an dosage of 100-150 mg/day for four 
weeks136. As SbV, miltefosine has a wide variety of secondary effects such as hepato- and 
renotoxicity137. Even though the mechanisms of action of miltefosine are not precisely 
understood, evidence suggests that it kills the parasite by inducing mitochondrial 
depolarization, decreasing ATP levels138 and interfering with the lipid metabolism139. The half-
life of miltefosine is approximately 120 hours. This renders it vulnerable to the emergence of 
drug resistance in Leishmania spp., because the parasite is exposed sub-therapeutic drug levels 
after completion of therapy140. 
 
 
4.2.5.3 Other Drugs 
Amphotericin B was developed as antifungal agent which has to be administered IV. It can be 
used in its plain or its liposomal form. The latter is usually better tolerated by the patients since 
28 
 
it has a similar efficacy but less side effects141. It is thought that its mechanism of action is the 
formation of pores in the parasite cell membrane through sterol binding142.  
Paromomycin is a broad spectrum antibiotic which can be also act against certain protozoan 
parasites by binding to their 30S ribosomal subunit and thus interfering with their protein 
synthesis. It can be administered topically or intramuscularly and can also cause severe side 
effects such as oto-, nephron- or hepatotoxicity 143. 
Pentamidine is another drug with antileishmanial properties. It is given in an intramuscular 
manner and its efficacy highly depends on the geographic region144,145. 
 
4.3 The Immune Response against Leishmaniasis 
4.3.1 The Innate Immune Response against Leishmaniasis 
When an infected sand fly bites a host and regurgitates Leishmania parasites, in addition 
immune modulatory molecules from the salivary glands are deposited at the site of infection116-
120. Together with the inflammation due to the injury of the skin and the skin capillaries, this 
results in rapid neutrophil recruitment9. The parasites are phagocytized by neutrophils, which 
eventually become apoptotic and the parasites are transferred eventually to the macrophages 
where they transform into amastigotes, their replicative form124. The role of neutrophils during 
these first hours of infection is of utmost importance. In the following two reviews “Different 
Leishmania Species Drive Distinct Neutrophil Functions” and “Survival Mechanisms Used by 
some Leishmania Species to Escape Neutrophil Killing” different aspects of the role of 
neutrophils in leishmaniasis are discussed. 
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4.3.1.1 Review 1: Different Leishmania Species Drive Distinct Neutrophil Functions 
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4.3.1.2 Review 2: Survival Mechanisms Used by some Leishmania Species to Escape 
Neutrophil Killing 
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4.3.1.3 Other Innate Immune Cells in Leishmaniasis 
The Leishmania-neutrophil interaction is very important during the first hours of infection. 
However, the parasite will be also taken up by other phagocytic cells. Dermal DCs and 
macrophages are known to take up parasites shortly after infection and dermal DCs migrate to 
the draining lymph node (dLN) for antigen (Ag) presentation120,146-148. Neutrophils recruited 
early after infection are known to recruit and activate macrophages to the site of infection in an 
MIP-1β dependent manner149,150. Furthermore, neutrophils recruit dendritic cells thorough 
CCL3 secretion to the infection site151. Also, inflammatory monocytes are recruited to the site 
of infection by a mechanism involving the secretion of platelet-derived growth factor by 
activated platelets which in turns leads to CCL2 secretion by leukocytes at the site of 
infection152. Once recruited, macrophages phagocytize apoptotic infected neutrophils as well as 
free parasites and become the main host for parasite replication. At the beginning of infection 
neutrophils are the predominant infected cell type but over time neutrophil numbers decrease 
and macrophages become the most infected cell population120. Macrophages are important 
effector cells in the destruction of intracellular parasites when activated by IFN-γ153. The 
antigen presenting moDCs phagocytize parasites and are crucial in the induction of adaptive 
immunity as they up-regulate MHC-II, migrate to the dLN for Ag presentation and are able to 
secrete IL-12 in order to induce a protective adaptive immune response154. Inflammatory 
monocytes take up parasites and are efficient in the killing of Leishmania parasites. CCR2-/- 
mice infected with L. major develop nonhealing lesions. Neutropenic Genista mice the 
increased resistance to L. mexicana infection correlated with the recruited inflammatory 
monocyte number, indicating an important role of these cells in immunity against 
leishmaniasis155. 
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4.3.1.4 Toll-like Receptors in Leishmaniasis 
The importance of Toll-like receptors in leishmaniasis is known since it has been described that 
mice lacking MyD88 are more susceptible to L. major infection than wild type mice156. 
Furthermore, it has been shown that the Leishmania surface structure lipophosphoglycan (LPG) 
is able to induce MyD88/TLR-signaling thorugh TLR2157. Also, it has been shown that Tlr2-/- 
mice infected with either L. major or L. mexicana subcutanoeusly in the rump developed bigger 
lesions and a higher parasite burden than their wild type counterparts158. Moreover, it is known 
that LPG-induced TLR2 siganling can lead to a inducation of NO production, an inhibition of 
phagosome maturation and a downregulation of TLR9 in macrophages159-161. Furthermore, it 
has been recently shown that TLR2 expressing nonhematopoietic cells are important in the 
neutrophil recruitment after L. major infection (Passelli, K. et al., 2018, manuscript submitted). 
LPG-TLR2-NK interactions have also been described to induce leishmanicidal functions in 
NK-cells160. Interesstingly, Tlr2-/- were able to better control L. donovani infection. Also, TLR4 
has been shown to be important in the control of L. major infection162. Tlr4-/- mice developed 
significantly bigger lesions than their wild type counterparts163. Futhermore, neutrophils were 
reported to induce macrophages mediated killing of L. major through neutrophil elastase in a 
TLR4 dependent manner164. The L. donovani derived glycoprotein gp29 was shown to be a 
TLR4 ligand and to induce IL-12 and NO production in L. donovani infected macrophages. 
Tlr3/7/9 tripple knock-out mice infected subcutaneously in the footpad with L. major were 
shown to be more susceptible to infection. These mice showed bigger lesions and a higher 
parasite burden with increased IL-10 and decreased IFN-γ levels. The Tlr3-/- showed no 
difference and the Tlr7-/- and Tlr9-/- only a very small difference in lesion size compared to the 
WT mice. However, it has been shown that the vaccination with soluble leishmania antigen 
(SLA) can be rendered successful by using TLR7 and TLR8 agonists as adjuvants165. Tlr9-/- 
mice infected with a high parasite inoculum have been shown to develop transiently bigger 
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lesion and higher parasite burden. It has further been shown, that TLR9 is important in the early 
NK cell activation166.  
 
4.3.2 The Adaptive Immune Response against Leishmaniasis 
Mouse models of L. major infection have shown that different mouse strains develop different 
disease phenotypes in response to infection. C57BL/6 mice that are infected with L. major 
LV39 develop small, self-healing lesions that heal over 8-12 weeks wherase BALB/c mice 
infected with the same parasite strain develop progressive nonhealing disease (Figure 9). The 
self-healing phenotype is associated with a strong Th1 response which leads to IFN-γ induced 
parasite killing through NO formation. The nonhealing phenotype is linked to a Th2 response 
that is characterised by a IL-4 mediated upregulation of agrinase prodcution that favors parasite 
survival in macrophages167-169. 
 
Figure 9: Lesion development of mice infected subcutaneously in the footpad with L. 
major 
 
Once an infection is established, antigen presenting cells such as moDCs will phagocyte 
parasites, migrate to the lymph node and interact with T-cells, which then get activated and 
proliferate. In C57BL/6 mice, the antigen presenting cells are triggered to produce IL-12 which 
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leads to the induction of  a Th1 response. In BALB/c mice the lack of IL-12 by antigen 
presenting cells leads to a Th2 response (Figure 9). 
 
Figure 9: Overview of the induction of adaptive immunity by L. major in mice (Sacks at 
al., 2002) 
 
The development of a Th1 response against Leishmania, the subsequent production of IFN-γ 
and TNF-α and the NO mediated killing of intracellular parasites in macrophages is also crucial 
in human disease. On the other hand, Th2 and Treg associated cytokines such as TGFβ or IL-
10 correlate with exacerbation of disease170-172. In many CL patients, the usual Th response 
ranges from a strong Th1 to a mixed Th1/Th2 response and the clinical presentation is a result 
from the balance or pro- and anti-inflammatory factors173-180. While a Th1 response is beneficial 
for disease development a too vigorous Th1 response to Leishmania infection can lead to tissue 
damage and an increased lesion development. Indeed, the lesion size of LCL patients correlates 
with the increase of IFN-γ and TNF-α secretion by CD4+ T-cells181,182. During the resolution of 
disease the intralesional IL-10 and TGF-β transcripts increase183,184. Tregs are also thought to 
be involved in the pathogenesis of LCL185,186. In MCL the levels of IFN-γ and TNF-α are even 
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higher than those observed in LCL patients. In addition, there are only few parasites found at 
the lesion site175. Furthermore, increased IL-17 expression found in lesion is suggestive of a 
role of Th17 response MCL pathogenesis187,188. This deregulation of pro- and anti-
inflammatory cytokines is thought to be one of the major driver of tissue destruction of MCL. 
In DL patients, the peripheral blood mononuclear cells (PBMCs) produce lower levels of Th1 
cytokines, however, the immune response at the site of infection is very similar and even more 
vigorous than in LCL189. In DCL patients, reduced numbers of IFN-γ producing cells and 
subsequently less NO production is found at the site of infection190. This disease manifestation 
is thought to be the result of the lack of an effective adaptive immune response and a 
predominance of anti-inflammatory cytokines (Figure 9). 
 
 
Figure 9: Spectrum of clinical presentations of the human cutaneous leishmaniasis (Scorza et al., 
2017) 
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5. Material and Methods 
The material and methods used in this thesis are included in the two manuscripts that are 
presented in part “6. Results”. 
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6. Aims 
The general aim of this thesis was the investigation of role of innate immunity in cutaneous 
leishmaniasis. This was done in two projects with separate foci. 
 
The focus of the first project was the assessment of the role or TLR7 in Leishmania major 
infection which was done aiming to investigating the following: 
1. Identification of cells expressing TLR7 upon L. major infection 
2. Characterization of the role of TLR7 in the adaptive immune response 
3. Influence of TLR7 in neutrophil recruitment, infection frequency and 
functionality 
4. Assessment of the mechanisms responsible for the differences in neutrophil 
activation 
5. Evaluation of the effect of early TLR7 signaling in neutrophils on disease 
outcome 
 
The focus of the second project was the investigation of the influence of Leishmania Viannia 
panamensis drug susceptibility phenotype on the neutrophil-parasite interactions aiming 
to elucidate the following: 
1. Assessment of the effect of L. (V.) p. drug susceptibility phenotype on the 
induction of neutrophil effector functions in human and mouse neutrophils 
2. Evaluation of the capability of L. (V.) p. that are resistant or susceptible to 
antileishmanial drugs to survive neutrophil mediated killing 
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7. Results 
The results of this thesis are presented in two manuscripts. In the first manuscript entitled “Early 
sensing of Leishmania major by Toll-like receptor 7 in neutrophils is essential for the control 
of cutaneous leishmaniasis” we investigated the role of TLR7 in murine L. major infection. We 
explored the role of TLR7 following injection of L. major at different site of infection. The 
results demonstrate the important role of TLR7 signaling in neutrophils early after infection 
and it impact on disease outcome. The second manuscript entitled “Resistance of Leishmania 
(Viannia) panamensis to meglumine antimoniate or miltefosine Modulates Neutrophil Effector 
Functions” investigates the influence of L. (V.) p. drug susceptibility phenotype on human and 
murine neutrophil activation and function.  From a common drug susceptible strain, a 
meglumine antimony and a miltefosine resistant L. (V.) p. line were derived and the interaction 
of these strains with neutrophils was assessed. Our data shows that drug resistant and drug 
susceptible parasites modulate neutrophil effector functions differently and that drug resistant 
parasites are more resistant to neutrophil mediated killing. 
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7.1 Manuscript 1 
Early Sensing of Leishmania major by Toll-like Receptor 7 in 
Neutrophils is Essential for the Control of Cutaneous Leishmaniasis 
 
Ivo Beat Regli, Berenice Martínez-Salazar, Katiuska Passelli, Benjamin P. Hurrell and 
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Summary 
Leishmania major (L. major) are protozoan parasites that cause cutaneous leishmaniasis. Upon 
infection with L. major, neutrophils are the predominant cells recruited locally and the first cells 
internalizing the parasites prior to their transfer into macrophages. In this study we investigated 
the importance of endosomal TLR7 signaling in neutrophils early after infection and its impact 
on disease outcome. In contrast to C57BL/6 mice that were able to heal their lesion and control 
parasite burden, L. major infected Tlr7-/- mice developed a chronic nonhealing lesion with 
partial parasite burden control, despite the development of a Th1 response similar to that 
observed in C57BL/6 mice. Twenty-four hours after infection, a higher frequency of infected 
neutrophils that contained a greater number of parasites per cell was observed in Tlr7-/- mice 
compared to C57BL/6 mice. Transcriptome analysis of infected dermal neutrophils at that time 
point revealed that L. major infection induced the upregulation of genes associated with 
immunity against leishmaniasis in C57BL/6 but not in Tlr7-/- neutrophils. The gene expression 
pattern observed in infected Tlr7-/- neutrophils suggested impaired neutrophil activation. In this 
line, L. major infected Tlr7-/- neutrophils showed impaired effector functions including 
decreased release of reactive oxygen species and neutrophil extracellular trap formation. 
Injection of Tlr7-/- neutrophils in neutropenic mice led to the development of chronic nonhealing 
lesion with partial parasite control. In contrast, injection of C57BL/6 neutrophils at the time of 
infection in neutropenic mice allowed subsequent lesion healing and parasite burden control. 
Conversely, C57BL/6 mice treated topically with a TLR7 agonist for the first three days of 
infection developed significantly smaller lesions than untreated mice. Collectively, our data 
show that early triggering of TLR7 signaling in neutrophils is playing an essential role in 
shaping the local microenvironment at the site of infection, impacting subsequent control of 
lesion development. 
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Introduction 
Cutaneous leishmaniasis is an important public health problem affecting 98 countries 
worldwide. Approximately 350 million people live in endemic areas and over 2 million new 
cases are reported annually (Alvar et al., 2012). Leishmania major is a causative agent of 
cutaneous leishmaniasis that is endemic in Africa, Asia and Europe. In most mouse strains such 
as C57BL/6, L. major causes the development of a spontaneously healing cutaneous lesion, 
which is associated with the development of a strong T-helper 1 response. These cells secrete 
IFN-γ, which activates macrophage microbicidal mechanisms leading to the elimination of the 
intracellular parasites. In contrast, a few strains such as BALB/c mice develop nonhealing 
progressive disease which is associated with the induction of a T-helper 2 response, which is 
characterized by IL-4 secretion, which impairs macrophage activation and results in parasite 
proliferation in these cells (Sacks and Noben-Trauth, 2002).  
L. major parasites expresse pathogen-associated molecular patterns (PAMPs) that can be 
recognized by pattern recognition receptors (PRR) expressed by leukocytes such as Toll-like 
receptors (TLR). TLRs recognize different PAMPs on the cell surface and in endosomes. They 
consist of leucin-rich repeats, a transmembrane region and a cytoplasmic signaling domain 
(Chandel et al., 2014, Takeuchi and Akira, 2010). Upon TLR activation, a signaling cascade is 
triggered that ultimately leads to the development of an immune response against the 
recognized pathogen, fostering innate immune cell activation and the secretion of pro-
inflammatory cytokines (Ashour, 2015). Mice lacking the myeloid differentiation factor 88 
(MyD88), showed a much higher susceptibility towards L. major than C57BL/6 wild type mice 
demonstrating an important role of the TLR receptors in leishmaniasis (Muraille et al., 2003; 
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Revaz-Breton et al., 2010). TLR signaling depends in most cases on the adaptor protein MyD88 
except in the case of TLR3 which signals in a MyD88-independent but TRIF-dependent manner 
and TLR4 that can trigger MyD88-dependent and TRIF-dependent signaling (Takeuchi and 
Akira, 2010). Most TLRs are expressed at the cell surface, however, TLR3, TLR7, TLR8 and 
TLR9 are exclusively expressed in the endosomal compartment. Tlr3/7/9 triple knock-out mice 
infected subcutaneously in the footpad with L. major were more susceptible to L. major 
infection than C57BL/6 mice demonstrating the importance of endosomal TLR signaling in L. 
major infection (Schamber-Reis et al., 2013). In addition, Tlr9-/- mice infected s.c. with L. major 
were shown to be transiently more susceptible to infection than C57BL/6 mice (Abou Fakher 
et al., 2009; Liese et al., 2007). TLR7 recognizes single-stranded RNA (ssRNA) and also 
responds to imidazoquinoline compounds such as imiquimod or resiquimod (Akira, 2006; 
Vasilakos and Tomai, 2013). Vaccination with soluble Leishmania antigen (SLA) could be 
improved using TLR7 agonists as adjuvants (Zhang and Matlashewski, 2008) and L. major was 
shown to induce Tlr7 mRNA expression in inflammatory C57BL/6 neutrophils (Charmoy et 
al., 2007). 
Neutrophils are the most abundant leukocyte in human circulation (Nauseef and Borregaard, 
2014). They possess three major effector killing strategies: Phagocytosis with the subsequent 
production of reactive oxygen species (ROS), the release of granules that contain microbicidal 
proteins and the formation of neutrophil extracellular traps (NETs) (Segal, 2005). NETs are 
fibrous structures composed of dsDNA coated with a variety of different microbicidal proteins 
that can trap and kill a variety of pathogens (Brinkmann et al., 2004). Upon phagocytosis of 
pathogens, neutrophils produce different reactive oxygen species that are synthesized by the 
enzymatic activity of NADPH-synthase (Roos et al., 2003). Neutrophil granules can either fuse 
with pathogen containing phagosomes or be released into the extracellular space (Mayadas et 
al., 2014). Following L. major infection, neutrophils are rapidly recruited to the site of infection 
in great numbers (Charmoy et al., 2007; Charmoy et al., 2016; Lee et al., 2018; Peters et al., 
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2008; Ribeiro-Gomes et al., 2014; Tacchini-Cottier et al., 2000). In many infections, neutrophils 
have a protective role, in leishmaniasis however, they can have a detrimental role following 
infection with some Leishmania spp. (Hurrell et al., 2016). In both mouse and human 
neutrophils, L. major parasites have been shown not only to survive but also to induce the 
release of chemokines that attract dendritic cells (DCs) (Charmoy et al., 2010). Furthermore, L. 
major can use neutrophils as “Trojan horses” to enter silently into the host macrophages 
(Laskay et al., 2003; van Zandbergen et al. 2004).   
In the present study, we aimed to establish the early role of TLR7 signaling in neutrophils 
during the first days of L. major infection. We showed that in absence of TLR7 neutrophil 
functions were impaired, changing parasite load and the microenvironment during the first days 
of infection, with consequences on the outcome of the disease.   
 
Material and Methods 
Ethics statement 
Animal experimentation protocols were approved by the veterinary office of the Canton of 
Vaud (Authorization 1266.6-7 to F.T.C.) and were done in accordance to cantonal and federal 
legislation as well as the principles of the declaration of Basel.  
 
Mice 
C57BL/6 mice were purchased from Envigo (Cambridgeshire, United Kingdom) and bred 
under specified pathogen-free conditions at the animal facility of the University of Lausanne in 
Epalinges. Tlr7-/- mice on a C57BL/6 background (backcrossed more than eight generations) 
were a gift from Prof. Shizuo Akira (University of Osaka, Japan). Genista mice (Ordonez-
Rueda et al., 2012) were a gift from Prof. Bernard Malissen (Centre d’Immunologie de 
Marseille-Luminy).  5 to 10 weeks-old mice were used in the experiments.   
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Leishmania major parasites  
Leishmania major LV39 parasites (MRHO/Sv/59/P strain) and L. major-mCherry (Passelli et 
al, submitted) were cultured in M199 medium with 10% fetal bovine serum (PAA 
Laboratories), 4% HEPES (Amimed) and 2% antibiotics (penicillin, streptomycin, neomycin, 
Invitrogen) at 26°C. Hygromycin B (PAA Laboratories) at a concentration of 50 µg/mL was 
added to the medium for the culture of L. major LV39 parasites (MRHO/Sv/59/P strain) 
expressing the mCherry red fluorescent protein. Metacyclic L. major parasites were isolated 
using a Ficoll (Sigma) density gradient. Parasites were re-suspended in M199 medium and 
layered on 10% and 20% Ficoll-medium suspension phases. After centrifugation at 1000 xg for 
15 minutes, metacyclic L. major parasites were isolated in the 10% Ficoll phase. The parasites 
were washed and counted and adjusted to a suitable concentration. 
 
Isolation of tissue cells 
Ears were recovered and processed into a single cell suspension. The two dermal layers were 
split and cut into small pieces, then digested in DMEM (Gibco) containing 0.2 mg/ml Liberase 
TL (Roche) for 2 hours at 37°C. Digestion was stopped by adding DMEM containing 5% FCS, 
1% HEPES Buffer, 1% PSN and 0.5% beta-mercaptoethanol. Subsequently, the tissue was 
mashed through a 40 µm filters (Falcon) to obtain a single cell suspension in medium. Footpads 
were recovered and processed into a single cell suspension. The skin was removed and the 
footpad tissue was separated from the bones. The recovered tissue was digested for 1 hour at 
37°C in HBSS (Invitrogen) containing 1 mg/ml CollagenaseD (Sigma). The digestion was 
stopped by the adding of DMEM containing 5% FCS, 1% HEPES Buffer, 1% PSN and 0.5% 
beta-mercaptoethanol and the tissue was filtered with 40 µm filters (Falcon). Lymph nodes were 
recovered, and cells were processed into a single cell suspension by mechanical 
homogenization 
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Neutrophil isolation 
Neutrophils were derived of bone marrow from femora and tibia of C57BL/6 mice and were 
isolated by negative MACS using the neutrophils isolation kit (Miltenyi Biotec) according to 
the manufacturer’s indications. Neutrophil purity was assessed using CytoSpin and Quick-Fix 
staining and was established to be >95%. 
 
Reactive oxygen species formation 
ROS production was measured using a luminol based chemiluminescence assay. Neutrophils 
were incubated in X-Vivo 15 Medium (Lonza) with either L. major, PMA or without stimulus 
in white, opaque 96-well plates (Perkin Elmer). Luminol (Carbosynth) was added at a final 
concentration of 20 µg/mL. ROS induced chemiluminescence was measured at a wavelength 
range from 400nm to 650nm. with a plate reader (Molecular Devices, SpectraMax MiniMax 
300) every 5 minutes for 1 hour. In vivo ROS production was measured with flow cytometry 
using the fluorescent probe DHR123 (Thermo Fisher). Whole ear cells were incubated with the 
probe for 30 minutes at 37°C. Then, the cells were stained with CD11b, Ly6G and with the 
Live/Dead fixable Aqua Dead Cell Stain Kit (Invitrogen) and run through the BD LSR-Fortessa 
(Becton Dickinson). Data was analyzed with the software FlowJo (Tree Star). 
 
Cytokine secretion 
Draining lymph node cells were incubated with UV treated (5 min) parasites, anti-CD3 antibody 
or without stimulus for 72 hours in DMEM with 5% FCS, 1% HEPES Buffer, 1% PSN and 
0.5% beta-mercaptoethanol. After incubation, cells were centrifuged at 500 xg for 5 minutes 
and supernatants were collected. IFN-γ and IL-4 production was assessed using enzyme linked 
immunosorbent assays (ELISA) according to the manufacturer’s instructions (BD Biosciences; 
R&D).  
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Analysis of parasite burden  
Single cell suspensions of infected tissues in biphasic medium (50 µL NNN medium containing 
20% of defibrinated rabbit blood and overlaid with 100 µL M199) were serially diluted in 96-
well plates and cultured for 7 days at 26°C in 8-fold replicates (Titus et al., 1985). The parasite 
number was determined from the lowest cell concentration from which promastigotes could be 
grown using the ESTIMFRE software which is based on the Poisson limit theorem as previously 
described. 
 
Flow cytometry 
Fluorescent parasites, stained parasites or stained murine cells were analyzed using Flow 
Cytometry analyzer of either the BD LSR II or the BD LSR-Fortessa series (Becton Dickinson) 
and analyzed with FlowJo software (Tree Star). The following antibodies were used for the 
identification of mouse antigen: anti-CD45-PerCPCy5, anti-CD8-APC, anti-CD4-AF700, anti-
Ly6G-APC, anti-CD11c-PECy7, anti-CD11b-PB, anti-CD62L-PE, anti-F4/80-APC, anti-
Ly6C-FITC, anti-Ly6G-APCCy7, anti-IFNγ-PECy7, anti-IFNγ-PE and anti-IL-4-FITC. For 
the assessment of cell viability: Live/Dead fixable Aqua Dead Cell Stain Kit (Invitrogen). 
 
Imaging flow cytometery 
An ImageStream cytometer (Amnis; Millipore Sigma, Billerica, MA, USA) at low speed and 
highest magnification (603) and the IDEA software was used to analyze samples. Internalized 
vs. noninternalized parasites were defined using the internalization of the bright parasite spots 
within the membrane marker mask. The following reagents were used for the identification of 
mouse antigens: Anti-Ly6G-APC-Cy7, anti-CD11b-FITC, anti-CD11b-PE-Cy5, anti-CD45-
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PerCP-Cy5.5 (eBioscience). The cell viability was assessed with DAPI (Sigma-Aldrich). 
 
Measurement of antioxidant capacity 
A redox sensor system was used (EDEL-for-life) to assess the antioxidant capacity in 
homogenized ears in PBS. This electrochemical-based method responds to all water soluble 
compounds with reducing potential in a given liquid sample (Liu et al., 2005; Liu et al., 2006). 
The reductive agents are oxidized within a defined potential range and the resulting current is 
measured and expressed in an arbitrary unit (EDEL). For low molecular weight antioxidants 
the relationship between potential and current within the defined potential range is linear 
(Sauvain et al., 2011). 
 
NET formation  
Neutrophils were seeded on Poly-L-Lysine coated coverslips and exposed for 4 hours with 
either L. (V.) p., PMA (Phorbol-12-myristate-13-acetate, Sigma), PMA + DNase (Sigma) or 
without stimulus. Subsequently, cells were fixed with 4% PFA (Paraformaldehyde, Sigma) and 
stained with rabbit anti-human MPO (Dako) primary antibody and Alexa Fluor-488 goat anti-
rabbit secondary antibody (Life Technologies). Coverslips were mounted on glass slides using 
a DAPI containing mounting medium (Molecular Probes) and analyzed by confocal microscopy 
(ZEISS LSM 510). 
NET formation was also assessed through the measurement of dsDNA in the supernatant using 
the Quant-iT PicoGreen kit (Thermo Fisher) by adapting a technique previously described 
(Amini et al., 2016). Neutrophils were primed with 25 ng/mL for 25 minutes at 37°C. 2x106 
Neutrophils were incubated for 4 hours in X-vivo medium (Lonza) with either L. (V.) p., PMA 
or PMA + DNase or without stimulus. After incubation, the cell suspensions were centrifuged, 
and the supernatants were collected and transferred into black 96-well plates (Perkin Elmer). 
The picogreen dye was added and fluorescence was measured in using a plate reader (Molecular 
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Devices, SpectraMax MiniMax 300) at an excitation wavelength of 480 nm and an emission 
wavelength of 520 nm. 
 
Transcriptome analysis 
Mice were infected with 106 metacyclic promastigotes of mCherry expressing L. major 
intradermally in the ear. Control mice were injected with 10µL PBS. Mice were put down, the 
ear excised and homogenized in PBS. The resulting cell suspension was stained with anti-
Ly6G-APCCy7. anti-CD11b-FITC and DAPI. Infected neutrophils and noninfected neutrophils 
from L. major infected mice and total neutrophils from PBS injected mice were FACS-sorted. 
The transcriptome was analyzed by RNA-sequencing carried out by Genewiz Inc. Data analysis 
was done with the support of Swiss Institute of Bioinformatics. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Results 
Intradermal L. major infection induces early upregulation of Tlr7 expression in the 
infected skin, a process correlating with neutrophil presence.  
In order to see whether TLR7 plays a role in the context of L. major infection, we infected 
C57BL/6 mice intradermally in the ear with 106 parasites or PBS. After 24 hours, the infected 
ears were collected and Tlr7 mRNA expression was analyzed in the ear cells. Tlr7 expression 
was more than two-fold upregulated in L. major infected ear compared to the levels measured 
in mice injected with PBS (Figure 1A). To determine if neutrophils contributed to Tlr7 
expression, we depleted neutrophils 4 hours before infection with L. major. Neutrophil-depleted 
mice expressed about three times less Tlr7 at the site of infection than WT mice injected with 
a control mAb (Figure 1A). These results indicate that most of the Tlr7 mRNA expression 
detected in the infected ear dermis 24 hours post infection is associated with the presence of 
neutrophils. Neutrophils are massively and rapidly recruited to the site of infection, a process 
that is more profound after intradermal injection compared to subcutaneous infection (Ribeiro-
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Gomes et al., 2014). As the early presence of neutrophils was shown to modulate the 
development of L. major immune response (Charmoy et al., 2007; Charmoy et al., 2016; Lee 
et al., 2018; Peters et al., 2008; Tacchini-Cottier et al., 2000), we analyzed if TLR7 signaling 
could influence neutrophil recruitment 24 hours post infection. To this end, mice genetically 
deficient in the Tlr7 gene (Tlr7-/-) and C57BL/6 mice were infected with 106 L. major and the 
composition of myeloid cells assessed in the infected tissues.  
 
Figure 1. Tlr7 expression in the ear and frequency of myeloid cells at the site of infection 24 hours after i.d. 
or s.c. L. major infection. A) Relative Tlr7 mRNA expression in the ear of C57BL/6 mice that were either 
injected with L. major or PBS. Mice were either depleted of neutrophils with the 1A8 antibody or injected with 
the RR3-16 control antibody. (B-D) Myeloid cell recruitment in mice that were injected with 106 metacyclic L. 
major promastigotes either i.d.in the ear or s.c in the footpad. After 24 hours, infected tissues were processed  
and analyzed by flow cytometry. The frequency of (A) CD45+ CD11b+ Ly6G+ cells neutrophils (B) CD45+ 
CD11b+ F4/80+ macrophages and (C) CD45+ CD11b+ CD11c+ DCs out of total CD11b+ cells present in the 
infected ear or footpad cells is shown . n≥3/group, * p-value<0.05. These are representative of two independent 
experiments. 
Marked differences in the type of myeloid cell recruited were observed depending on the site 
of L. major infection. Following intradermal infection, the frequency of recruited neutrophils 
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was two times higher than that observed following subcutaneous infection, while the frequency 
of macrophages was two times lower than that observed following subcutaneous infection 
(Figure 1B-D). These data are in line a previous report (Ribeiro-Gomes et al., 2014). However, 
both Tlr7-/- and C57BL/6 mice showed a similar frequency of myeloid cell recruitment to the 
site of infection, suggesting that TLR7 signaling does not impact early myeloid recruitment to 
the site of L. major infection.   
 
TLR7 is essential for the control of the disease following intradermal but not 
subcutaneous L. major infection 
The genetic absence of Tlr7 was reported to have only a minor impact on lesion development 
and parasite control following s.c. infection with L. major (Schamber-Reis et al., 2013). In line 
with these results, we did not observe any impact on lesion development, parasite load and 
immune response following s.c. infection with 5x105 L. major (Figure S1). Here we showed 
that Tlr7 mRNA expression correlated with neutrophil presence, and that a significantly higher 
frequency of neutrophils was recruited to the site of infection following i.d. infection. We 
therefore postulated that if TLR7 was playing a role in neutrophils following L. major infection, 
this could be better observed following i.d. infection. Thus, Tlr7-/- and C57BL/6 mice were 
infected with 105 L. major in the ear dermis. In addition, Myd88-/- mice were included in the 
experiments as a control of nonhealing lesion development. L. major-infected Tlr7-/- mice 
developed chronic nonhealing lesion that did not necrose in contrast to C57BL/6 mice that 
healed their lesion. Myd88-/- mice developed faster progressive nonhealing lesion (Figure 2A-
B) that necrosed 10 weeks post infection. Analysis of the parasite burden at the site of infection 
as well as in the dLNs 10 weeks post infection revealed that Tlr7-/- mice had a ten times higher 
parasite burden than C57BL/6 mice. Nevertheless, Tlr7-/- mice controlled their parasite load 
better than Myd88-/- mice (Figure 2C). 
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Figure S1. Lesion Development, parasite burden and cytokine secretion after L, major infection of C57Bl/6 
WT and Tlr7-/- mice. Mice were injected with 5x105 L. major metacyclic promastigotes s.c.in the footpad A) 
Lesion development. B) Parasite burden in the footpad 10 weeks after infection.  C) IFN-γ  and D) IL-4 
expression in CD45+ CD4+ T cells in the footpad 10 weeks post infection E) IFN-γ and F) IL-4 secretion of dLN 
cells restimulated with UV-treated L. major. Data representative of 2 independent experiments, n≥3/group, * p-
value<0.05, ** p-value<0.01. 
 
Next, we analyzed the development of T-helper cells, analyzing the production of IFN-γ and 
IL-4 in T-cells at the site of infection by flow cytometry. A high frequency of CD4+ IFNγ+ T 
cells was observed at the site of infection of L. major infected Tlr7-/- and C57BL/6 mice and no 
difference was observed between both groups (Figure 2D). In addition, no differences in the 
level of IFN-γ secretion was observed in dLN cells of C57BL/6 and Tlr7-/- infected mice, as 
analyzed by ELISA following antigen restimulation in vitro (Figure 2F). The frequency of 
CD4+IL-4+ producing cells and IL-4 secreted levels at the site of infection and in dLN cells as 
very low in both groups of mice (Figure 2D-G). These data demonstrate that Tlr7-/- mice are 
fully able to develop a Th1 type of immune response following infection.    
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Figure 2. Lesion Development, parasite burden and cytokine secretion after L, major infection of C57Bl/6 
WT and Tlr7-/- mice. Mice were injected with 105 L. major metacyclic promastigotes intradermally in the ear A) 
Lesion development B) Representative pictures of lesions in the ear 8 weeks after infection. C) Parasite burden in 
the ear 10 weeks after infection. D) IFN-γ expression in CD45+ CD4+ cells in the ear 10 weeks post infection. E) 
IL-4 expression in CD45+ CD4+ cells in the ear 10 weeks post infection F) IFN-γ secretion of dLN cells 
restimulated with UV-treated L. major. G) IL-4 secretion of dLN cells restimulated with UV-treated L. major.  H) 
Relative amount of IgG1 found in the sera of mice I) Relative amount of IgG2a found in the sera of mice. Parasite 
burden was measured with limiting dilution analysis. For cytokine expression measurements cells were stained 
with fluorochrome coupled antibodies and the frequency CD45+ CD4+ cells expressing either IFNγ or IL-4 was 
measured by flow cytometry. IFNγ and IL-4 secretion as well and IgG concentrations were measured with ELISA. 
Data representative of 6 individual experiments, n≥5/group, * p-value<0.05, ** p-value<0.01. 
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In contrast, Myd88-/- mice showed markedly decreased IFN-γ and an increased IL-4 levels at 
the site of infection or after restimulation of dLN cells, indicative of the development of a Th2 
response (Figure 2D-G). In line with these data, low levels of IgG1 indicating low IL-4 and 
IL-13 presence and high levels of IgG2c indicative of high levels of IFN-γ presence were 
observed in the serum of infected C57BL/6 and Tlr7-/- mice while elevated levels of IgG1 and 
low levels of IgG2c were observed Myd88-/- mice (Figure 2H-I). Collectively, these data show 
that despite the development of nonhealing chronic lesion, L. major infection induces the 
development of Th1 cells in Tlr7-/- mice.   
 
Absence of TLR7 results in higher parasite frequency in neutrophils and more elevated 
parasite number per neutrophils 
As the adaptive immune type 1 immune response developed normally in Tlr7-/- mice, we next 
investigated the impact of TLR7 absence on early parasite burden in neutrophils. To this end, 
Tlr7-/- and C57BL/6 mice were infected i.d. with 106 metacyclic L. major-mCherry parasites in 
the ear. The frequency of infected neutrophils in the infected ear dermis was determined by 
flow cytometry 24 hours later. The frequency of recruited neutrophils was similar between both 
groups of mice as shown before. However, the frequency of L. major infected neutrophils was 
three times higher in Tlr7-/- cells than in C57BL/6 neutrophils (Figure 3A-B). Further analysis 
of infected neutrophils by imaging flow cytometry additionally showed that Tlr7-/- neutrophils 
harbored more parasites per cell than C57BL/6 neutrophils 24 hours after infection (Figure 3C-
D). To further estimate the number of live parasites presented in the ear 24 hours post infection, 
we performed limiting dilution analysis (LDA). The number of parasites observed in the ears 
of infected Tlr7-/- mice was significantly higher than that observed in ears of C57BL/6 mice 
(Figure 3.E). Similarly, a higher number of parasites survived in Tlr7-/- neutrophils compared 
to to C57BL/6 neutrophils in vitro (Figure 3F).  
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Figure 3. Neutrophil recruitment and infection 24 hours post infection in the ear. Mice were injected with 106 mCherry 
expressing metacyclic L. major promastigotes. After 24 hours mice were sacrificed, the infected ears were excised and 
homogenized, digested and the cell content was analyzed by flow cytometry. A) CD45+ CD11b+ Ly6G+ neutrophils frequency 
out of total CD45+ CD11b+ cells at the site of infection. B) Infected L. major-mCherry+CD45+ CD11b+ Ly6G+ neutrophil 
frequency out of total neutrophils at the site of infection C) Representative images taken by imaging flow cytometry showing 
infected neutrophils. D) Number of parasites per infected neutrophils E) Parasite burden in the ear analyzed by LDA F) Number 
of L. major-mCherry infected parasites after in vitro coincubation of L. major and neutrophils.  Results of ≥2 representative 
experiments,  n≥6/group, * p-value<0.05. 
 
 
L. major-infected dermal neutrophils induce upregulation of genes associated to an 
antileishmanial immune response in C57BL/6 mice but not in Tlr7-/- mice. 
To further investigate the role of TLR7 in neutrophils at the onset of L. major infection, we 
FACS sorted infected dermal neutrophils from the ears of Tlr7-/- and C57BL/6 mice infected 
with 106 L. major metacyclic promastigotes for 24 hours. As controls, ear neutrophils recruited 
following injection with PBS were similarly isolated. We sequenced the transcriptome of these 
neutrophils and analyzed the gene expression of C57BL/6 and Tlr7-/- infected neutrophils and 
compared them to that obtained in neutrophils from C57BL/6 and Tlr7-/- mice injected with 
PBS. Gene-ontology (GO) analysis revealed that genes associated with IFN-γ synthesis, cellular 
response to nitric oxide, positive regulation of macrophage migration, granulocyte 
differentiation, IL-2 synthesis and the defense response to protozoan were upregulated in 
C57BL/6 mice. All these processes are linked to an effective immune response to L. major.  
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Figure 4. Transcriptome analysis of C57BL/6 and Tlr7-/- dermal neutrophils infected or not with L. major. 
C57BL/6 and Tlr7-/- mice were injected with 106 metacyclic L. major promastigotes or 10µl PBS intradermally in 
the ear. The mRNAs of FACS sorted dermal neutrophils from infected mice were compared to that from dermal 
neutrophils of mice injected with PBS. A) Representation of manually selected clusters with their associated GO-
Terms B) Number of significantly differentially up- and downregulated genes between C57BL/6 and Tlr7-/- L. 
major infected or PBS recruited neutrophils C) Differences of gene expression of 22 selected genes associated with 
the GO-Term “Oxidation-reduction process” between L. major infected and PBS recruited neutrophils in C57BL/6 
and Tlr7-/- mice. 
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In contrast, in infected Tlr7-/- a different gene expression pattern was observed, with 
downregulation of genes associated with the negative regulation of the extrinsic apoptotic 
signaling pathway, the positive regulation of NF-κB signaling and the response to transforming 
growth factor beta. This gene expression pattern suggested decreased neutrophil activation 
(Figure 4A). Further analysis of significantly differentially regulated genes in neutrophils of 
both mouse strains revealed that there are more genes upregulated in infected C57BL/6 
neutrophils compared to infected Tlr7-/- neutrophils, further suggesting a lower neutrophil 
activation in Tlr7-/- neutrophils (Figure 4B). Genes associated to oxidation/reduction processes 
that are important in the innate immune response against L. major were upregulated in infected 
C57BL/6 neutrophils but were downregulated in infected Tlr7-/- neutrophils (Figure 4C). Taken 
together, these data show that the absence of TLR7 differentially modulates the transcriptional 
neutrophil response against L. major suggesting an impact on neutrophil effector functions. 
 
L. major triggering of TLR7 expression contributes to neutrophil effector functions  
The transcriptome analysis performed in L. major infected or noninfected neutrophils suggested 
that the absence of TLR7 would negatively modulate neutrophil effector functions at the onset 
of infection. To confirm this, Tlr7-/- and C57BL/6 bone marrow-derived neutrophils were 
infected with metacyclic L. major parasites at a multiplicity of infection (MOI) of 5 and the 
chemiluminescence induced by the reaction of luminol with ROS analyzed over 80 minutes. 
ROS production by C57BL/6 neutrophils was significantly more elevated than that measured 
in Tlr7-/- neutrophils. High levels of ROS were observed following PMA stimulation, and no 
difference were observed between Tlr7-/- and C57BL/6 neutrophils suggesting that the deficient 
ROS production observed in Tlr7-/- neutrophils is L. major specific (Figure 5A). To analyze if 
impaired ROS production would similarly be observed in vivo, C57BL/6 and Tlr7-/- mice were 
infected with L. major and 24 hours later the fluorescent oxidative species dye DHR123 was 
added to the isolated ear cell suspension to analyze in vivo ROS production by flow cytometry. 
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In line with the in vitro data, the frequency of Tlr7-/- neutrophils producing ROS was markedly 
lower than that observed in C57BL/6 neutrophils (Figure 5B-C). 
 
 
Figure 5. Induction of ROS and NET formation in Tlr7-/- and C57BL/6 neutrophils following L. major 
infection A-D) Sorted bone marrow derived neutrophils from Tlr7-/- and C57BL/6 mice were kept in luminol 
containing medium and exposed to either metacyclic L. major promastigotes at a MOI of 5 (A) or the TLR7 agonist 
imiquimod (E) ROS formation was assessed by measuring luminol chemiluminescence. Data are shown as an 
arbitrary scale, RLU = relative light units.. B+C) Mice were injected with 106 metacyclic L. major mCherry 
promastigotes. After 24 hours mice were put down, the infected ears excised, homogenized, digested and ROS 
formation was measured with DHR123 and analyzed by flow cytometry. One representative histogram (B) and 
MFI of one representative experiment are shown (C). D) The antioxidant capacity of homogenized ears was 
measured by measuring the conduction characteristics. Measurements indicated on an arbitrary scale (EDEL). F) 
Measurement of NET formation by quantification of dsDNA released by murine neutrophils upon exposure to L. 
major promastigotes for 4 hours at a MOI of 5. G) Representative confocal microscopy pictures of neutrophils 
forming NETs upon challenge with L. major. One representative experiment out of ≥3 is shown in each graph. 
n≥3/group, * p-value<0.05 
 
 
The antioxidant capacity of homogenized ears of both mouse strains 24 hours post infection 
was analyzed. Conversely, we could show that Tlr7-/- mouse ears had a higher antioxidant 
capacity than C57BL/6 mouse ears and thus had been less subject to oxidative stress (Figure 
5D). 
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Given that the absence of TLR7 leads to a decreased L. major induced ROS production, we 
next measured if the stimulation of C57BL/6 neutrophils with a TLR7 agonist, imiquimod, 
would induce ROS production. Stimulation with imiquimod alone did not induce ROS 
production, however, the co-stimulation of these neutrophils with L. major and imiquimod led 
to increased ROS production compared to that obtained following stimulation with L. major 
alone (Figure 5E).   
To then assess NET formation in response to L. major, we measured the release of dsDNA by 
neutrophils challenged with L. major in vitro using the picogreen fluorescence assay. A 
significant decrease in dsDNA correlating with NET release was observed in Tlr7-/- neutrophils 
compared to C57BL/6 neutrophils (Figure 5F). Furthermore, these data were confirmed by 
confocal microscopy analysis of NET forming neutrophils staining DNA with DAPI and the 
NET associated myeloperoxidase (MPO) with a mAb against MPO (Figure 5G). Altogether, 
these data show that Tlr7-/- mice have impaired neutrophil effector functions and therefore are 
likely less able to control infection during the first 24 hours.  
 
TLR7 activation on neutrophils early after infection determines disease progression over 
time 
To establish the importance of TLR7 signaling early after infection we applied imiquimod on 
the ears of C57BL/6 mice one day before as well as one and three days after infection in order 
to stimulate TLR7 signaling. Mice treated with imiquimod at the onset of infection developed 
smaller lesions than untreated C57BL/6 mice and had a lower parasite burden 12 weeks post 
infection (Figure 6A-C). A similar elevated frequency of CD4+ IFN-γ+ T cells and a low 
frequency of CD4+ IL-4+ T cells was observed in both treated or untreated group of mice 
(Figure 6D-E). These data demonstrate that early TLR7 activation has an influence on the 
development of the inflammatory lesion but not on the development of Th1 cells. This is in line 
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with the increased parasite numbers observed in Tlr7-/- mice compared to C57BL/6 mice 24 
hours after infection (Figure 3E). 
Figure 6. Disease evolution after infection of C57BL/6 with 105 L. major metacyclic promastigotes 
intradermally in the ear and topical treatment with 5% imiquimod cream at the onset of infection. A) 
Representative pictures of ear lesions 11 weeks after infection of C57BL/6 mice treated or not with 5% imiquimod 
cream at the onset of infection B) Lesion development in mice treated or not with 5% imiquimod cream. C) Parasite 
burden in the ear 11 weeks after infection D) The frequency of CD4+CD45+IFN-γ+ and E) of  CD4+CD45+IL-4+ T 
cells was analyzed by flow cytometry at the site of infection 11 weeks post infection. This is a representative 
experiment out of three, n≥4/group, * p-value<0.05  
 
 
In order to further assess the importance of neutrophil function during the first 24 hours in 
disease phenotype we infected neutropenic Genista mice with 105 L. major together with either 
106 Tlr7-/- or 106 C57BL/6 neutrophils. Mice injected with Tlr7-/- neutrophils at the onset of 
infection developed nonhealing chronic lesion that were very similar to those observed 
following infection of Tlr7-/- mice (Figure 7A-B) and a higher parasite burden was observed in 
the infected ears 12 weeks post infection compared to similarly infected mice injected with 
C57BL/6 neutrophils at the onset of infection (Figure 7C). 
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Figure 7. Diseases outcome following transfer of C57BL/6 or Tlr7-/- neutrophils in neutropenic Genista mice 
at the onset of infection. A) Representative pictures of lesion observed in the ear 12weeks after infection. B) 
Lesion development in mice transferred with C57BL/6 or Tlr7-/- neutrophils at the onset of infection C) Parasite 
burden in the ear of the indicated groups 10 weeks after infection D) Frequency of CD4+ CD45+ IFNγ+and E) CD4+ 
CD45+ IL-4+ T cells in infected ears 12 weeks post infection. Data are representative of three experiments 
n≥3/group, * p-value<0.05 
 
An equally strong Th1 response developed in both groups of mice, as determined by the high 
frequency of CD45+ CD4+ IFN-γ+ T cells present at the site of infection (Figure 7D-E). These 
data demonstrate a predominant role of TLR7 signaling in neutrophils at the onset of infection 
which has consequences on the outcome of infection.  
 
Discussion  
In this study we show that the early triggering of TLR7 signaling in neutrophils plays an 
important role in the protective defense against L. major infection. The importance of Toll-like 
receptors in leishmaniasis has been established since early studies describing that mice lacking 
MyD88, a common signaling molecule on the pathway for the most of TLRs, are more 
susceptible to L. major infection than C57BL/6 mice (de Veer et al. 2003; Muraille et al., 2003). 
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Here, we show that activation of the endosomal TLR7 in neutrophils early after infection is a 
major player in the control of the cutaneous lesion and parasite load. 
Of note, we show that the absence of TLR7 influences the diesease development of intradermal 
but not subcuteaneous L. major infection. Human disease is established parasites are deposited 
into the dermal and epidermal layers by a sand fly bite. We and others have shown that myeloid 
recuitment of cells differs between subcutaneous injections and intradermal injection. Thus, 
intradermal needle inoculation of parasites is thought to be clinically more relevant (Ribeiro-
Gomes et al., 2014). Nevertheless in a majority of cases, sand flies deposit less than 1000 L. 
major in the dermis (Kimblin et al., 2008). In nature, sand fly derived factors have been shown 
to contribute to neutrophil recruitment to the site of infection (de Moura et al., 2010; Peters et 
al. 2008; Silva al. 2005; Teixeira et al., 2005). Due to the lack of those factors, we infected mice 
with 106 parasitse looking at neutrophil recruitment. When assessing lesion development, we 
infected mice with 105 L. major since we have observed that a lower inoculum did not change 
the disease phenotype but only delayed the disease onset (data not shown). To assure a high 
enough parasite inoculum we infected 5x105 parasites when looking at development of 
subcutaneous infection. 
Neutrophils have been shown to have a deleterious function in infection with a variety of 
Leishmania spp. but to be able to efficiently kill parasites in a few Leishmania spp. such as L. 
amazonensis (Hurrell et al., 2016). Genista mice are neutropenic mice due to a point mutation 
in the transcrption al repressor Growth Factor Independence 1 (Gfi1). Here we show that 
Genista mice infected with L. major and simultaneously injected with Tlr7-/- neutrophils 
developed chronic nonhealing lesion that resembles those observed following infection of Tlr7-
/- mice. In contrast, similarly infected mice injected with wild type neutrophils were able to 
resolve their lesion size and control their paraite load.  These data suggest that transit through 
neutrophils and the initial parasite load in these cells influences the microenvironment and 
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parasite load early in infection, with consequences on the subsequent control of lesion 
development, a process controlled by TLR7 signaling.  
The decrease observed in neutrophil effector functions and the resulting higher parasite load 
observed in these cells during the first days of infection suggested decreased neutrophil killing 
functions. However, neutrophils were reported to act as shelter for the silent entry of L. major 
parasites into macrophages. Despite ROS production and NET formation, L. major was 
reported to survive in neutrophils (Aga et al., 2002; Laskay et al., 2003; Laufs et al., 2002; van 
Zandbergen et al., 2004). The results presented here suggest either that a small proportion of 
parasites are killed in C57BL/6 neutrophils, a process dependent on TLR7 and/or that L. major 
may survive better in Tlr7-/-. In absence of TLR7, L. major may even be able to replilcate in 
neutrophils as was previously reported for L. mexicana (Hurrell 2017), an hypothesis that needs 
to be further tested.  
The development of Th1 cells was not impacted in absence of TLR7 and despite high levels of 
IFN-γ that were similar to those observed in draining lymph nodes and infected ears of C57BL/6 
mice, the parasite load observed up to 30 weeks after infection was roughly 10 times higher in 
infected ears of Tlr7-/- mice than in infected ears of C57BL/6 mice. The frequency of C57BL/6 
and Tlr7-/- infected macrophages was similar during the first day of infection. Tlr7-/- BM-derived 
macrophages infected with L. major had the same infection frequency than C57BL/6 
macrophages. However, one cannot exclude a possible role of TLR7 signaling in macrophages 
later in infection, contributing to the increased parasite burden observed in Tlr7-/- mice. 
Preferential targetting of the parasites to distinct subset of dermal macrophages was recently 
reported to allow the development of inflammatory lesion despite the elevated levels of IFN-γ 
at the site of infection (Lee 2018). In absence of TLR7 signaling, it is possible that L. major 
LV39 targetting of dermal macrophages is modified, a process that will need further 
investigation. 
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We report here that a lack of TLR7 signaling leads to an increase in lesion size. However, the 
development of nonhealing lesion did not coincide with a altered T-helper response. 
Collectively these data demonstrate that while Th1 cells and IFN-γ production are important in 
immunity against L. major infection, they are not the only determinant of disease outcome. 
These data are in line with previous reports showing that an other L. major clinical strain 
isolated from a chronic LCL patient, L major Seidmann (L.m.Sd.), induces nonhealing lesions 
in C57BL/6 mice despite the induction of a strong Th1 response (Charmoy et al., 2016). 
Here, RNA-sequencing was performed for the first time in L. major infected neutrophils. We 
compared infected and noninfected neutrophils of L. major infected C57BL/6 and Tlr7-/- mice. 
Furthermore, we compared those neutrophils to neutrophils recruited in mice injected with PBS. 
Interestingly, we did find very similar gene expression patterns when comparing infected with 
noninfected neutrophils derived from the same infected mice. This indicates that gene 
expression is mainly driven by the lesion environment and that L. major uptake per se has not 
a big influence on gene expression. Therefore, we focused on the comparison of infected 
neutrophils of L. major infected mice with neutrophils from mice injected with PBS. We could 
show that upon infection of C57BL/6 mice, in neutrophils a series of genes associated to 
immunity against L. major are positively regulated. In contrast, in Tlr7-/- we saw a down-
regulation of another series of genes indicative of a lack of neutrophil activation. Thus, the 
neutrophil response against L. major infection differs on a transcriptional level between Tlr7-/- 
or C57BL/6 neutrophils. Here, we have analyzed the gene expression of selected genes that are 
assigned to the GO-term “oxidation-reduction processes”. We focused on that term because it 
is known that ROS and NO production are important oxidative processes that are involved in 
the antileishmanial immune response. Assessing further the biological relevance of the 
pathways indicated by the gene ontology analysis would be important to further understand the 
exact function of L. major has in neutrophil biology. 
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Here, we are showing for the first time the importance of TLR7 signaling in neutrophils in the 
context of leishmaniasis. TLR7 and TLR8 are closely related endosomal TLRs that recognize 
ssRNA. Human neutrophils express TLR8, however, TLR7 expression in human neurophils is 
controversial. In contrast, in mice, TLR7 is expressed in mouse neutrophils. Moreover, in 
contrast to human neutrophils, murine TLR8 has been reported not to be functional (Liu et al., 
2010). It is thought that murine TLR7 and human TLR8 have some common functions. For 
instance, it was reported that HIV-1 derived guanosine and uridine rich ssRNA oligonucleotides 
are recognized by murine TLR7 but human TLR8191. Intracellular human neutrophil stimulation 
with ssRNA and TLR8 agonists was previoulsy reported to lead to increased ROS production 
and neutrophil degranulation (Janke et al., 2009). Furthermore, stimultion of TLR8 led to 
priming of the NADPH oxidase activation in human neutrophils (Makni-Maalej et al., 2015). 
Here, we show that the stimulation of murine neutrophils with the TLR7 agonist imiquimod did 
not lead to increased in ROS formation. However, in vitro stimulation with L. major together 
with this agonist led to an increase in ROS formation compared to L. major stimulation alone. 
Together with the decrease of ROS production observed in Tlr7-/- neutrophils compared to wild 
type neutrophils follwoing exposure to L. major, our results indicate that TLR7 plays an 
important role in neutrophil activation in murine neutrophils. In human nuetrophils, TLR8 is 
likely to have similar functions than TLR7 in murine neutrophils. Furthermore, we show here 
that early activation of TLR7 by topical treatment prior and during the first day after L. major 
infection leads to an important decrease of lesion size, further stressing the importance of TLR7 
signaling early after infection. In this sense, topical application of imiquimod in combination 
with meglumine antimony was reported to be beneficial to disease outcome in leishmaniasis 
patients (Arevalo et al., 2007; Miranda-Verastegui et al., 2005; Miranda-Verastegui et al., 
2009). Even though imiquimod was applied at different time points than in our study and the 
study was done in Peru, thus involved New World species, these findings still indicate a 
therapeutic potential of TLR7/TLR8 activation human lesihmaniasis. However, imiquimod has 
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not yet been shown to be beneficial in the treatment of leishmaniasis caused by Old World 
species. (Al-Mutairi et al., 2009; Firooz et al., 2006; Seeberger et al., 2003). Nonetheless, it 
would be concivable that TLR7/TLR8 signaling in cutaneous leishmaniasis patients could exert 
neutrophil activating properties and lead to a beneficial disease outcome since it is known that 
neutrophils are found in significant numbers in chronic experimental cutaneous leishmaniasis 
lesions (Hurrell et al., 2016). Moreover, imiquimod used as an adjuvant vaccine administered 
toghether with soluble leishmanial antigen was able to induce IFN-γ in spleen cells of BALB/c 
mice (Zhang and Matlashewski, 2008).  
We show here that Tlr7-/- and Myd88-/- mice developed bigger lesions than C57BL/6 mice, but 
Tlr7-/- mice were better able to control lesion size and parasite burden than Myd88-/- mice. 
Myd88-/- mice are not able to signal after TLR-ligand engagement, except following TLR3 and 
partially TLR4 triggering (Kawai and Akira, 2011). TLR2 signaling can lead to an inhibition 
of phagosome maturation and a downregulation of TLR9 in macrophages supporting the 
survival of the parasites (Kavoosi et al., 2010; Srivastava et al., 2013). Furthermore, it has been 
reported that TLR2 expressing nonhematopoietic cells are important in the neutrophil 
recruitment after L. major infection (Passelli, K. et al. 2018, submitted). On the other hand, 
TLR9 was reported to enhance phagocytic function in neutrophils (Prince et al., 2011). All these 
process should still take place in Tlr7-/- and could at least partially explain the differences in 
disease progression observed between Tlr7-/- and Myd88-/- mice.  
In conclusion, our results demonstrate the critical importance of TLR7 signaling in neutrophils 
early in infection, with an impact on subsequent resolution and control of L. major infection. 
Furthermore our data highlight the importance of innate immune response early after infection 
in leishmaniasis disease progression.  
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Abstract  
Leishmania (Viannia) panamensis (L. (V.) p.) is the main causative agent of cutaneous 
leishmaniasis in Colombia and is usually treated with either meglumine antimoniate (MA) or 
miltefosine (MIL). In recent years, there has been increasing evidence of the emergence of drug 
resistance against these compounds. Neutrophils are known to play an important role in 
immunity against Leishmania. These cells are rapidly recruited upon infection and are also 
present in chronic lesions. However, their involvement in the outcome of infection with drug 
resistant Leishmania has not been examined. In this study, human and murine neutrophils were 
infected in vitro with MA or MIL drug resistant L. (V.) p. lines derived from a parental L. (V.) 
p. drug susceptible strain. Neutrophil effector functions were assessed analyzing the production 
of reactive oxygen species (ROS), the formation of neutrophil extracellular trap (NET) and the 
expression of cell surface activation markers. Parasite killing by neutrophils was assessed using 
L. (V.) p. transfected with a luciferase reporter. We show here that MA and MIL resistant L. 
(V.) p. lines elicited significantly increased NET formation and MA resistant L. (V.) p. elicited 
significantly increased ROS production in both murine and human neutrophils, compared to 
infections with the parental MIL and MA susceptible strain. Furthermore, neutrophils exposed 
to drug resistant lines showed increased activation, as revealed by decreased expression of 
CD62L and increased expression of CD66b in human neutrophils. In contrast, L. (V.) p. lines 
resistant to either MA or MIL presented higher survival within neutrophils than the drug 
susceptible strain. 
These results provide evidence that parasite drug susceptibility influences neutrophil activation 
and function as well as parasite survival within neutrophils. Further studies on the impact of 
drug susceptibility on neutrophil effector function should contribute to better understanding of 
the factors involved in susceptibility to antileishmanial drugs. 
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Introduction 
Cutaneous leishmaniasis is an important public health problem affecting 98 countries 
worldwide. Approximately 350 million people live in endemic areas and over 2 million new 
cases are reported annually (Alvar et al., 2012). In Colombia, L. (V.) p. is responsible for the 
majority of reported cases of cutaneous leishmaniasis (Ramirez et al., 2016) though L. (V) 
braziliensis may be more frequent among occupationally exposed military personnel (Patino et 
al., 2017). The first line of treatment in Latin America (Organización Panamericana de la Salud, 
2013) and most of the world, consists of parenteral administration of meglumine antimoniate 
(MA) (Mitropoulos et al., 2010). Oral miltefosine (MIL) is generally administered as the second 
line treatment. In recent years, there has been an increasing number of reports of treatment 
failure and loss of susceptibility of clinical Leishmania strains to antimonial drugs, and 
association of resistance in some cases of therapeutic failure in leishmaniasis patients. The 
reported frequency of MA and MIL tolerance ranges from 10 to 70% and varies among 
Leishmania species and by geographic origin. The underlying mechanisms contributing to 
antileishmanial treatment failure in Colombia and the rest of the world are poorly understood 
(Goyeneche-Patino et al., 2008; Rojas et al., 2006; Obonaga et al., 2014). 
It is well established that the outcome of antileishmanial treatment is not solely dependent on 
parasite drug susceptibility, but also on intrinsic host factors. The interplay between parasites, 
the host and the immune response is also a factor determining the clinical outcome of 
Leishmania infection and treatment (Croft et al., 2006; Uliana et al., 2018). There is currently 
a lack of information on the role of neutrophils in Leishmania infection and its impact on drug 
susceptibility. Recently, high levels of transcriptional signatures associated with chemokines 
promoting neutrophil recruitment were observed in L. (V.) p. infected primary macrophages 
and in chronic cutaneous lesions of CL patients, suggesting a potential role for neutrophils in 
the chronicity of infection (Navas et al., 2014). Neutrophils are essential phagocytes of the 
innate immune system and the most abundant leukocytes in human circulation (Nauseef and 
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Borregaard, 2014). They usually are the first cells recruited to the site of infection upon 
pathogen entry into a host (Branzk and Papayannopoulos, 2013). Neutrophils possess three 
major effector killing strategies: phagocytosis and subsequent production of reactive oxygen 
species (ROS), the release of granules that contain microbicidal proteins (Segal, 2005) and the 
formation of neutrophil extracellular traps (NETs). NETs are fibrous structures composed of 
dsDNA coated with a variety of different microbicidal proteins that can trap and kill a variety 
of pathogens (Brinkmann et al., 2004). Upon phagocytosis of pathogens, neutrophils produce 
different reactive oxygen species that are synthesized by the enzymatic activity of NADPH-
synthase (Roos et al., 2003). Indeed, a lack of NADPH-synthase function manifests itself in 
higher susceptibility to a variety of infections and is known as chronic granulomatous disease 
(Thomas, 2018). Also a lack of Myeloperoxidase (MPO), an enzyme that catalyzes the synthesis 
of highly microbicidal hypochlorous acid, is thought to lead to increased susceptibility to 
infection (Winterbourn et al., 2016). Neutrophil granules can either fuse with pathogen 
containing phagosomes or be released into the extracellular space (Mayadas et al., 2014). 
Increasing evidence points towards a crucial role of neutrophils in leishmaniasis (Ribeiro-
Gomes and Sacks, 2012; Hurrell et al., 2016). It has been shown that neutrophils are massively 
recruited to the site of infection upon infection with L. major (Lee et al., 2018; Peters et al., 
2008; Ribeiro-Gomes et al., 2014; Tacchini-Cottier et al., 2000),  L. amazonensis (Sousa et al., 
2014), L. braziliensis (Falcao et al., 2015), L. mexicana (Hurrell et al., 2015), L. infantum 
(Thalhofer et al., 2011) and L. donovani (Dey et al., 2018; McFarlane et al., 2011) and that a 
subset of L. mexicana can even use these cells to replicate (Hurrell et al., 2017). While 
neutrophils are well known to have a protective role in many infections they can have either 
beneficial or detrimental roles in leishmaniasis depending on the Leishmania spp. involved192. 
In most studies performed in murine models, the lack of neutrophils was beneficial to disease 
outcome in Leishmania infection. Furthermore, parasites are known to use these cells as “Trojan 
horses” to enter silently into the host macrophages (Laskay et al., 2003). In contrast, neutrophil 
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presence has been reported to positively affect disease outcome in the case of L. braziliensis 
(Souza-Lemos et al., 2008; Novais et al., 2009; Carlsen et al., 2015; Falcao et al., 2015), L. 
amazonensis (Tavares et al., 2014) and L. donovani infection (McFarlane et al., 2008).  
Here, using human and mouse neutrophils, we have investigated in vitro the role of these cells 
in the context of antileishmanial drug resistance following L. (V.) p. infection. We found that 
L. (V.) p. lines with different drug susceptibility have different effects on neutrophil phenotype 
and functionality. Our data show that neutrophils are differentially activated by drug resistant 
and drug susceptible parasites and that drug resistant parasites are less affected by neutrophil 
killing than drug susceptible parasites. These differences in the elicitation of neutrophil function 
and parasite killing may influence antileishmanial drug therapy. 
 
Materials and Methods 
Mice 
C57BL/6 mice (5-10 weeks old) were purchased from Envigo (Cambridgeshire, United 
Kingdom) and bred under specified pathogen-free conditions at the animal facility of the 
University of Lausanne in Epalinges.  
 
Ethics statement 
All procedures involving human blood samples were approved by the Ethical Committee of the 
Canton of Vaud (CER-VD 2017-00182). Written informed consent was obtained from the 
healthy blood donors participating in this study. The study was conducted in compliance with 
the legislation of the Canton of Vaud and the Swiss Confederation as well as the declaration of 
Helsinki. Animal experimentation protocols were approved by the veterinary office of the 
Canton of Vaud (Authorization 1266.6-7 to F.T-C.) and were done in accordance to cantonal 
and federal legislation as well as the principles of the declaration of Basel. This study and the 
use of patient derived Leishmania strains and lines was approved by the Ethics Committees of 
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CIDEIM- Colombia, in accordance with the national and international guidelines for Good 
Clinical Practice.    
 
Leishmania (Viannia) panamensis parasites  
The L. (V.) p. strain (MHOM/COL/86/1166LUC) WT-control was used to generate the strains 
resistant to potassium antimony (III) tartrate hydrate and miltefosine as described previously 
(Brochu et al., 2003). Briefly, L. (V.) p. promastigotes were cultured in media containing 
increasing concentrations of drugs, either up to 2885 µM Sb or up to 60 µM of miltefosine. 
Upon establishment of drug resistance, the strains were cultured in RPMI (Gibco) with 10% 
FCS and 1% PSN at 26°C. Antimony resistant parasites were cultured in medium containing 1 
mM Sb. Miltefosine resistant strains were cultured in medium containing 60 µM miltefosine. 
Luciferase expressing strains were grown in medium containing 60 µM G418 (Sigma) 
 
SNARF-1 staining of Leishmania (Viannia) panamensis parasites 
Parasites were stained with the intracellular dye SNARF-1 (Thermofisher) to render them 
fluorescent. Parasites were incubated in 6 µM solution of SNARF-1 in PBS for 30 minutes and 
subsequently washed twice. SNARF-1 stained fluorescent parasites were detected at an 
excitation wavelength of 488 nm and an emission wavelength of 610 nm. 
 
Drug susceptibility screening 
Drug susceptibility of parasites was measured as a reduction of intracellular L. (V.) p. 
amastigote burden in macrophages derived from a U-937 cell line as described previously 
(Fernandez et al., 2012). Briefly, 1.2×105 U-937 cells were treated with phorbol 12-myristate 
13-acetate (PMA; 100 ng/ml; Sigma) to differentiate them into macrophages. Cells were 
cocultured with L. (V.) p. promastigotes opsonized with 10% AB positive human serum at a 
MOI of 5:1 and incubated for 24 hours at 34°C. Subsequently, the culture medium was replaced 
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with RPMI containing either 16 µM miltefosine or 32 µg/ml Sb(V) and the cells were incubated 
for another 48 hours. The Sb-containing medium was replaced after 24 hours whereas the 
miltefosine-containing medium was not replaced during the 48 hours of incubation. Parasite 
burden was assessed by light microscopy in four replicates by 2 microscopists in a blinded 
manner. The cut-offs defining sensitive respectively resistant strains were based on a previously 
published analysis (Fernandez et al., 2012). 
 
Isolation metacyclic Leishmania (Viannia) panamensis parasites 
Metacyclic L. (V.) p.  parasites were isolated using a Percoll (GE Healthcare) density gradient. 
Parasites were resuspended in 45% Percoll-medium suspension and layered onto 60% and 90% 
Percoll-medium suspension phases. After centrifugation without brakes at 4300 xg for 45 
minutes, metacyclic parasites were isolated from the 45%/60% Percoll-medium suspension 
interphase (Castilho et al., 2010). The parasites were washed twice and counted using a 
Neubauer chamber. 
 
Human neutrophil isolation 
Peripheral blood neutrophils were isolated from venous blood of healthy volunteers. Density 
gradient centrifugation using PolymorphPrep (Progen) was performed and the enriched 
neutrophils were isolated according to the manufacturer’s instructions. The remaining red blood 
cells were lysed using ACK-Buffer. Neutrophil purity was assessed using Cyto-Spin and Quick-
Fix staining and was established to be ≥ 95%. 
Murine neutrophil isolation 
Bone marrow of the femora and tibia of C57BL/6 mice were flushed with RPMI. Erythrocytes 
were lysed with ACK buffer, the remaining leukocytes were washed and the neutrophils were 
then isolated by negative MACS using the neutrophil isolation kit (Miltenyi Biotec) according 
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to the manufacturer’s indications. 
 
Assessment of NET formation  
3x105 Neutrophils were seeded on poly-L-Lysine coated coverslips, primed with 25ng/mL GM-
CSF and exposed for 4 hours with either L. (V.) p., L. major, PMA (Phorbol-12-myristate-13-
acetate, Sigma), PMA + DNase (Sigma) or without a stimulus. Subsequently, cells were fixed 
with 4% PFA (Paraformaldehyde, Sigma) and stained with rabbit anti-human MPO (Dako) 
primary antibody and Alexa Fluor-488 goat anti-rabbit secondary antibody (Life Technologies). 
Coverslips were mounted on glass slides using a DAPI containing mounting medium 
(Molecular Probes) and analyzed by confocal microscopy (ZEISS LSM 510).  To quantify NET 
formation, NETs were counted using fluorescence microscopy in a blinded manner based, at 
least in three replicates. NET formation was also assessed through the measurement of dsDNA 
in the supernatant using the Quant-iT PicoGreen kit (Thermo Fisher) by adapting a technique 
previously described (Amini et al., 2016). 2x106 neutrophils were incubated for 4 hours in X-
vivo medium (Lonza) with either L. (V.) p., PMA or PMA + DNase or without stimulus. After 
incubation, the cell suspensions were centrifuged, and the supernatants were collected and 
transferred into black 96-well plates (Perkin Elmer). The picogreen dye was added and 
fluorescence was measured in using a plate reader (Molecular Devices, SpectraMax MiniMax 
300) at an excitation wavelength of 480 nm and an emission wavelength of 520 nm.  
 
Measurement of reactive oxygen species production 
ROS production was measured using a luminol-based chemiluminescence assay. 5x105 
neutrophils were incubated with either L. (V.) p., PMA or without stimulus in white, opaque 
96-well plates (Perkin Elmer). Luminol (Carbosynth) was added at a final concentration of 20 
µg/mL. ROS induced chemiluminescence was measured at all wavelengths with a plate reader 
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at 5 minutes intervals during 1 hour. 
 
Parasite viability measurement with luciferase assay 
5x105 neutrophils were infected with luciferase-expressing L. (V.) p. strains with different drug 
susceptibility phenotypes during 2 hours at 34°C at a MOI of 5, washed and subsequently 
incubated for 24 hours. Parasite viability after incubation was measured using a luciferase assay 
system (Promega) according to the manufacturer’s instructions. Chemiluminescence was 
measured in white, opaque 96-well plates in a plate reader (Molecular Devices, SpectraMax 
MiniMax 300) at all wavelengths. 
 
Identification of neutrophil cell surface markers and measurement of cell viability by flow 
cytometry 
Surface activation markers and cell viability markers in blood derived human neutrophils were 
analyzed using Flow Cytometry analyzer of either the BD LSR II or the BD LSR Fortessa series 
(Becton Dickinson) and analyzed with FlowJo software (Tree Star). The following antibodies 
were used: Anti-human: CD15-APC, CD62L-PerCP-efluor710, CD66b-PE-Cy7. Anti-mouse: 
Ly6G(1A8)-APC-Cy7, CD62L-PE, CD11b-PE-Cy7 (all from e-Bioscience). Cell viability: 
Live/Dead fixable Aqua Dead Cell Stain Kit (Invitrogen). 
 
 
 
Results 
Increased reactive oxygen species production by murine and human neutrophils 
challenged with miltefosine resistant Leishmania (Viannia) panamensis strains 
To investigate the contribution of neutrophils in the intracellular survival of Leishmania during 
drug exposure, we first investigated whether L. (V.) p. strains susceptible or resistant to MA or 
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MIL would induce different phenotype and function in neutrophils. The production of ROS by 
neutrophils is known to be an important defense mechanism against pathogens (Nguyen et al., 
2017) and also contribute to NET formation (Papayannopoulos, 2015). 
 
Figure 1. MIL resistant L. (V.) p. parasites induce more ROS production in murine and human neutrophils 
than the MA resistant or drug susceptible strains. ROS production was measured using a luminol based 
chemiluminescence assay. Bone marrow derived murine neutrophils and blood-derived human neutrophils from 
healthy donors were incubated with either MIL resistant, MA resistant or susceptible L. (V.) p., PMA or without 
stimulus. Luminol was added and ROS induced chemiluminescence was measured with a plate reader every 5 
minutes during 1 hour. A,C) One representative curve of ROS-induced luminol chemiluminescence values in 
murine (A) and human (C) neutrophils. B,D) The corresponding area under the curve (AUC) of 60 minutes of 
measurement for murine (B) and human (D) neutrophils. * p<0.05, *a MIL-R compared to WT, *b MIL-R 
compared to MA-R, WT: Wild type, MA-R: Resistant to meglumine antimoniate, MIL-R: Resistant to miltefosine, 
the data are pooled out of three (human) or two (mouse) independent experiments. 
 
Therefore, we analyzed ROS production during the first hour of incubation of neutrophils with 
the different L. (V.) p. populations. Parasites that are resistant to miltefosine induced 1.5 times 
more ROS production compared to drug susceptible parasites in BM-derived murine 
neutrophils (Figure 1 A,B) and more than two times as much ROS production than drug 
susceptible parasites in blood-derived human neutrophils from healthy donors (Figure 1 C,D). 
In contrast, the induction of ROS by antimony resistant parasites and drug susceptible L. (V.) 
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p. strains in neutrophils did not differ from that of drug susceptible parasites. Even though all 
L. (V.) p. strains induced ROS in neutrophils, these results show that the drug susceptibility 
phenotype, specifically MIL resistance, influences neutrophil ROS production. 
 
Drug resistant Leishmania (Viannia) panamensis induce more neutrophil extracellular 
trap formation than drug susceptible strains in murine and human neutrophils 
Next, to visualize NETs, neutrophils were infected with L. (V.) p. of different drug susceptibility 
and NET formation analyzed by confocal microscopy. NETs were stained with DAPI to detect 
DNA filaments and an MPO mAb to detect the MPO associated with it. All parasite populations 
tested induced NET formation in both murine and human neutrophils as observed by DNA-
MPO colocalization (Figure 2A). MIL and MA resistant L. (V.) p. induced substantially more 
NETs (two to three times) in murine and human neutrophils compared to drug susceptible 
parasites (Figure 2 B-C).  
We observed parasites in association with the NETs, a process more easily detectable in human 
NETs. To confirm these results, we used the picogreen assay that measures the amount of 
dsDNA released by neutrophils into the supernatant (Amini et al., 2016). We again observed 
that drug resistant L. (V.) p. parasites induced a significantly higher amount of dsDNA release 
compared to drug susceptible parasites in human and murine neutrophils (Figure 3). 
Collectively, these results demonstrate that MIL and MA resistant L. (V.) p lines induce more 
NET formation than the parental drug susceptible strain. 
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Figure 2. Murine and human neutrophils form more NETs when exposed to L. (V) p. strains that are 
resistant to either MA or MIL. Neutrophils were seeded on poly-L-Lysine coated coverslips and exposed for 4 
hours with either L. (V.) p. of the indicated drug susceptibility, PMA, PMA + DNase or without stimulus. 
Subsequently, cells were fixed, stained with anti-human MPO and DAPI A) Confocal microscopy images of 
murine or human neutrophils exposed to SNARF-1 labeled L. (V.) p. promastigotes lines that were either resistant 
or susceptible to MA or MIL at parasite-cell MOI of 5. B-C). The frequency of murine (B) or human (C) 
neutrophils forming NETs was counted with a fluorescence microscope. * p<0.05, each point corresponds to one 
healthy blood donor or one mouse. One representative experiment out of four is shown. 
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Modulation of neutrophil cell surface activation markers by Leishmania (Viannia) 
panamensis of different drug susceptibility phenotypes 
We next investigated if exposure of neutrophils to L. (V.) p. of different drug susceptibility 
would result in distinct modulations of cell surface markers. Using flow cytometry, we observed 
that BM derived murine neutrophils exposed to MIL and MA drug resistant L. (V.) p lines 
expressed more CD11b (Mac-1) and CD62L (L-selectin) on their surface than neutrophils 
exposed to drug susceptible L. (V.) p. (Figure 4). 
 
Figure 3. Murine and human neutrophils release more dsDNA when exposed to L. (V) p. strains that are 
resistant to either MA or MIL. Bone marrow derived murine neutrophils (A) and blood derived human 
neutrophils from healthy donors (B) were exposed to L. (V.) p. of the indicated susceptibility at a MOI of 5. As 
controls, incubations with PMA, PMA + DNase or without stimulus were also performed. Four hours later, NET 
formation was quantified by measuring the levels of double stranded DNA (dsDNA) released in the supernatant 
using the PicoGreen fluorescent dye assay. * p<0.05, *a MA-R or MIL-R compared to WT, *b MIL-R compared 
to MA-R, Each point corresponds to one healthy blood donor or one mouse. One representative experiment out of 
four (human) and three (mice) independent experiments is shown. 
 
CD62L and CD66b (exocytosis of secondary granules) expression by human neutrophils 
derived from the blood of healthy individuals exposed to drug susceptible and resistant L. (V.) 
p revealed that MA and MIL resistant parasites elicited a decrease in expression of CD62L and 
an increase in expression of CD66b (Figure 5). These data show that both human and murine 
neutrophils exposed to drug resistant L. (V.) p. lines are activated to a greater extent and have a 
phenotype that is more associated with extravasation, compared to neutrophils challenged with 
drug susceptible L. (V.) p.  
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Drug resistant Leishmania (Viannia) panamensis strains are more resistant to neutrophil 
parasite killing 24 hours after infection 
As we observed differences in ROS production, NET formation and neutrophil activation in 
neutrophils exposed to L. (V.) p. of different drug susceptibility phenotypes, we assessed 
whether this would have an impact on parasite killing.  
Figure 4. Expression of cell surface activation markers of murine neutrophils in response to exposure to L. 
(V.) p. promastigotes with different drug susceptibility phenotypes. Bone marrow derived murine neutrophils 
were exposed to the indicated L. (V.) p. lines at a MOI of 10 or incubated without stimulus for 90 minutes. 
Incubation with PMA was used as a positive control. Neutrophils were then stained with the CD11b and CD62L 
mAbs and surface expression was analyzed by flow cytometry. A-B) A representative flow cytometry plot of 
normalized fluorescence values of murine neutrophils stained with antibodies against CD11b and CD62L is shown. 
C-D) MFI values of murine neutrophils stained with antibodies against CD62L and CD11b. WT: Wild type, MA-
R: Resistant to meglumine antimoniate, MIL-R: Resistant to miltefosine. The data is representative of three 
experiments. * p<0.05 
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Luciferase expressing L. (V.) p. lines of the indicated drug susceptibility phenotypes were 
exposed to murine or human neutrophils for 24 hours and parasite viability was analyzed by 
measuring luciferase activity. 
 
 
Figure 5. Expression of surface activation markers of human neutrophils in response to exposure to L. (V.)  
p. metacyclic promastigotes of different drug susceptibility phenotypes. Blood-derived neutrophils from 
healthy donors were exposed to the indicated L. (V.) p. lines at a MOI of 10 or incubated without stimulus for 90 
minutes. Incubation with PMA was used as a positive control. Neutrophils were then stained with the CD62L and 
CD66b mAbs and surface expression was analyzed by flow cytometry. A-B) One representative flow cytometry 
plot of normalized fluorescence values of human neutrophils stained with antibodies against CD62L and CD66b 
is shown C-D) MFI values of human neutrophils stained with antibodies against CD62L and CD11b. WT: Wild 
type, MA-R: Resistant to meglumine antimoniate, MIL-R: Resistant to miltefosine. The data is representative of a 
total of five experiments. * p<0.05 
 
Drug resistant parasites were significantly more resistant to neutrophil killing by murine and 
human neutrophils than the drug susceptible strain (Figure 6). Taken together, our data 
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demonstrate that, in both murine and human neutrophils, drug resistant L. (V.) p. lines induce 
more mechanisms known to kill pathogens than the drug susceptible parasites, yet are better 
able to resist neutrophil killing. 
 
Figure 6. Killing of L. (V.) p. of different drug susceptibilities by murine and human neutrophils. Neutrophils 
were infected with luciferase expressing L. (V.) p. lines with different drug susceptibility phenotypes for 2 hours 
at 34°C, washed and further incubated for 24 hours prior to analysis. Parasite viability after incubation was 
measured using a luciferase assay system. Murine (A) and human (B) neutrophils were exposed to luciferase 
expressing L. (V.) p. of the indicated drug susceptibility at a MOI of 5. 24 hours later chemiluminescence was 
measured represented as relative light units and parasite killing was assessed MIL-R: Resistant to miltefosine, 
MA-R: Resistant to meglumine antimoniate, freeze-thaw parasites were killed by 10 cycles of freezing and 
subsqequent thawing, PMN: Neutrophils, One representative experiment is shown out of four. 
 
Discussion 
Antileishmanial drug resistance is an increasing concern in Colombia, but also worldwide 
(Azeredo-Coutinho et al., 2007; Bilbao-Ramos et al., 2017; Fernandez et al., 2014). In India, 
miltefosine has replaced antimony as the first line of treatment against visceral leishmaniasis 
due to widespread evidence of antimony resistance (Vanaerschot et al., 2011). However, the 
efficacy of miltefosine has also dropped considerably during the first ten years following its 
introduction (Rijal et al., 2013; Sundar et al., 2013; Sundar and Chakravarty, 2012). It is crucial 
to consider that parasite drug resistance is not equal to clinical treatment failure. Therapeutic 
response is also determined by host factors, such as previous infection, comorbidities, 
nutritional status, pharmacokinetics etc. (Castro et al., 2017). 
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Nevertheless, drug resistance is a very important determinant of treatment failure, thus 
understanding how drug resistance phenotype of L. (V.) p. impacts the antileishmanial immune 
response is relevant to the understanding of the potential role of neutrophils in therapeutic 
outcome. 
Here, we have demonstrated for the first time that L. (V.) p. parasites having different drug 
susceptibility phenotypes elicit distinct neutrophil effector functions, shown by a higher 
induction of ROS production, NET formation and the expression of surface markers 
characteristic of neutrophil activation. ROS production is a crucial microbicidal mechanism of 
neutrophils, but the impact of ROS on Leishmania survival is species and host dependent (Regli 
et al., 2017). Here, we showed that L. (V.) p. induces ROS production in murine and human 
neutrophils and that ROS production is increased when murine and human neutrophils are 
infected with the miltefosine resistant L (V.) p. compared to the drug susceptible parasites. It 
has been reported that ROS production is critical for the induction of ROS-dependent NET 
formation (Branzk et al., 2014). Activation and nuclear translocation of neutrophil elastase are 
crucial in ROS-dependent NET formation, reviewed in (Papayannopoulos, 2018) and 
(Brinkmann, 2018). However, there is also an NOX-independent pathway of NET formation 
that does not depend on ROS (Manfredi et al., 2018). L. amazonensis has been reported to 
induce ROS-independent and ROS-dependent NET formation. In our study, we show that MA 
resistant and MIL resistant L. (V.) p. induce more NET formation than drugg susceptible strain, 
however only MIL resistant L. (V.) p. induced an increased ROS production. These data 
suggests that the NET formation induced by MA resistant L. (V.) p. may be partly ROS-
independent. 
Neutrophil effector functions contribute to microbial destruction in most infections, however, 
their role in leishmaniasis varies, depending on host factors and the Leishmania spp. involved 
(Hurrell et al., 2016; Regli et al., 2017). We observed L. (V.) p. parasites associated with the 
filamentous structures of NETs, which substantiates parasite trapping by these structures. Most 
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Leishmania spp. are trapped by NETs. Some, such as L. mexicana (Hurrell et al., 2015), L. 
donovani (Gabriel et al., 2010) or L. infantum (Guimaraes-Costa et al., 2014) survive NET 
exposure, while others such as L. amazonensis (Guimaraes-Costa et al., 2009; Guimaraes-Costa 
et al., 2014; Rochael et al., 2015) are killed by NETs, at least in their promastigote stage. The 
higher survival of drug resistant parasites despite induction of greater ROS and NET response 
suggests that these L. (V.) p. lines resist better to neutrophil killing than L. (V.) p. susceptible 
strains. This is in line with studies performed on macrophages, reporting that MA as well as 
MIL resistant Leishmania donovani strains were more resistant to ROS mediated killing due to 
increased intracellular thiol-levels. (Das et al., 2013; Deep et al., 2017 ; Mandal et al., 2007; 
Mishra and Singh, 2013 ; Mittal et al., 2007). Neutrophil recruitment and increased neutrophil 
activation are known to play a key role in many inflammatory diseases (Delgado-Rizo et al., 
2017; Yang et al., 2016). Our results demonstrate that there is an increase in neutrophil 
activation upon stimulation by drug resistant L. (V.) p. compared to drug susceptible parasites. 
It is therefore conceivable that treatment failure may result at least in part due to the increased 
resistance of L. (V.) p. strains to neutrophil effector functions. An increase in parasite survival 
would then lead to an increase of inflammation and in turn would lead to more neutrophil 
recruitment and activation, and potentially constitute a self-sustaining circle. 
In this study, we used laboratory-derived L. (V.) p. drug resistant lines. Since there are 
differences in the drug resistance mechanisms of parasites that develop drug resistance in vivo 
compared to those experimentally selected for drug resistance in vitro (Ashutosh et al., 2007; 
Goyeneche-Patino et al., 2008) the assessment of the interaction of neutrophils and L. (V.) p. 
with different drug susceptibility phenotypes that have been isolated from patients in a clinical 
setting should further elucidate of the role of the interaction of L. (V.) p. and neutrophils in 
antileishmanial therapy. Also, the study of the in vivo immune response, notably of neutrophils, 
against those parasites would contribute to better understanding of the role the immune system 
plays in antileishmanial treatment outcome. 
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Further understanding of the impact of drug resistant parasites on neutrophil function, including 
the analysis ROS production and NET formation ex vivo (e.g. from lesion biopsies or patient 
blood samples), should be further investigated to assess if this neutrophil activation could 
constitute be used a surrogate marker for predicting the expected treatment outcome success in 
a given patient.  
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8. Perspectives 
8.1 Leishmania Major Inoculation Doses Used in in Vivo Mouse Models  
In nature, Phlebotomus inoculate  low numbers of parasites into the dermis and epidermis. In 
75% of cases, the L. major inocculum has been reported to be lower then 103 parasites. 
However, the number can reach up to 105 parasites in rare cases116. Upon Lutzomyia bites, 
factors derived from the sand fly have been shown to contribute to neutrophil 
recruitment117,118,193. Upon Phlebotomus bites in mice ears, a marked neutrophil recruitment 
into the dermis was observed (Peters et al., 2008). During our studies of L. major infection in 
mice we tested different inoculation doses. To compensate for the lack of sand fly derived 
factors, we infected higher parasite numbers than normally transmitted by sandflies. We made 
the observation that in mice intradermally infected with of 104 L. major the disease onset was 
delayed compared to mice injected with 105 parasites while the disease outcome did not change. 
It has been reported for L. major Friedlin and L. major Seidman that a needle inoculation of as 
few as 1000 parasites is sufficient to induce a lesion194. However, also in these cases the disease 
onset was delayed in comparison to the inoculation of 105 L. major. For practical reasons, in 
the experimental settings where a robust neutrophil recruitment at 24 hours was needed, we 
injected mice with 106 L. major parasites which corresponds to the inoculum used in other 
studies195,196. Differences in parasite numbers led to differences in disease dynamics but not in 
disease outcome. We showed that neutrophils are important determinants of diseases 
progression. Therefore, it can be assumed that neutrophils are also recruited in relevant numbers 
upon injection of lower parasite numbers. However, the exact dynamics of neutrophil 
recruitment and L. major needle inoculation has yet to be determined. Finally, to even better 
determine the neutrophil-parasite dynamics in human disease, it would be desirable to measure 
neutrophil recruitment and neutrophil infection and neutrophil effector functions in a mouse 
model where the parasite is transmitted through sand flies. 
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8.2 Potential Interest in the Development of a Mouse Model of 
Leishmania (Viannia) Panamensis Infection 
L. (V.) p. is known to have a poor infectivity in mice. However, the many immunological and 
genetical tools that are available in mice would make it a worthwhile in vivo model to study. 
Some strains of L. (V.) p. injected subcutaneously at a high inoculum (107) are able to establish 
an infection in BALB/c mice197. By using monoclonal antibodies that recognize antigens which 
are upregulated in amastigotes, Castilho et al. developed a BALB/c model of a chronic L. (V.) 
p. infection which can be induced by a low parasite inoculum (104)198. The laboratory-derived 
L. (V.) p. lines that were used in this thesis were not able to establish an infection in BALB/c 
mice, neither using a low nor a high parasite inoculum (data not shown). However, we were 
able to establish infection using clinically isolated drug resistant L. (V). p. strains. In preliminary 
experiments, we could establish that miltefosine resistant and antimony resistant parasites 
induced bigger lesions than drug susceptible parasites. In order to further elucidate the effect of 
L. (V.) p. drug susceptibility on neutrophils it would be important to assess whether our in vitro 
findings obtained in laboratory-derived drug resistant strains can be reproduced in the in vivo 
mouse model. It would be of interest to determine whether differences in neutrophil activation 
could be used as surrogate markers for predicting the expected treatment outcome. Furthermore, 
it could be assessed if a given strain that induces treatment failure in patients also induces 
treatment failure in mice. Such a mouse model could be used for the adjustment and 
improvement of treatment modalities. Finally, the mouse model could also be used to further 
investigate the basic immunological mechanisms and the effects of parasite drug susceptibility 
phenotype on the immune response against L. (V.) p.  
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8.3 Potential Additional Roles of Toll-Like Receptor 7 in Immunity 
against Leishmania major 
pDCs are specialized cells that are able to produce high amounts of Type-1 interferon upon 
TLR7 and TLR9 signaling199. pDCs have been found in the skin and in the draining lymph-
nodes of L. major infected mice200. Furthermore, it has been shown that pDCs pulsed with L 
major lysate and transferred into BALB/c mice induced protection against L. major infection201. 
Moreover, pDCs are able to produce IFN-β upon TLR7 activation through bacterial nucleic 
acids62. Indeed, low doses of IFN-β have been shown to have a protective effect against L. 
major infection in BALB/c mice and to lead to an increase of IFN-γ production in T-cells and 
an increase of IL-12 and iNOS expression in the draining lymph-node of infected mice202. 
Furthermore, it has been reported that iNOS expression early after infection is type-1 IFN 
dependent203. However, other studies show that type-1 signaling is irrelevant for L. major 
infection disease development204. In neutrophils, type-1 interferon can activate the expression 
of the cytotoxic molecule tumor necrosis factor related apoptosis inducing ligand (TRAIL). In 
tumor-associated neutrophils, IFN-β induces a more antitumoral phenotype 205. Here, we 
demonstrated that the absence of TLR7 leads to an increase in disease severity following L. 
major infection. Therefore, it could be hypothesized that in absence of TLR7 a dysfunctional 
DC response and an alteration in type-1 IFN secretion may contribute to the development of 
nonhealing lesion and parasite replication202-204. Of note, there is evidence indicating that type-
1 IFN are capable to modulate neutrophil effector function, which in turn would inflect the 
leishmaniasis disease progression.  
TLR7 activation in a subset of monocytes characterized by low CD14 expression is thought to 
be involved in the tissue innate immune surveillance. Upon activation these cells secrete IL-1β 
and TNFα. IL-1β and TNF-α have the ability to prime neutrophils for increased ROS formation 
which presumably would positively influence disease progression in L. major infection206,207. 
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Furthermore, CD14high monocytes secrete high levels of IL-8, IL-6 and IL-12 upon TLR7 
signaling64,65. IL-12 is an important mediator in the shaping of a protective Th1 response and is 
also important in the NK-cell mediated IFN-γ secretion65,169. Moreover, inflammatory 
monocytes are thought to play an important role in the immune response against L. mexicana155. 
It is thus conceivable that following L. major infection, TLR7-mediated inflammatory 
monocyte activation could be beneficial in leishmaniasis disease outcome.  
NK-cells secrete IFN-γ upon TLR7 signaling and are involved in the immunity against L. major 
early after subcutaneous infection65,166. The absence of TLR7 is possibly a cause of an 
inadequate NK-cell response to L. major infection with an inappropriate IFN-γ secretion and 
could contribute to the exacerbation of the disease phenotype. However, the role of NK-cells in 
intradermal L. major infection has yet to be established. 
Even though we showed that TLR7 signaling in neutrophils early after infection is of utmost 
importance in the immune response against L. major, it has to be considered that TLR7 
signaling might also contribute to other pathways involved in a successful immune response 
against L. major.  
 
8.4 Species Specific Differences in Endosomal Single-Stranded RNA 
Recognition 
Here, we used a mouse model on C57BL/6 background to show the importance of TLR7 
signaling in neutrophils after L. major infection. To transfer these findings to a clinical setting 
it has to be considered that human neutrophils do not express TLR769. In humans TLR7 and 
TLR8 both recognize ssRNA59 but the exact scope of the structures recognized by these 
receptors is species-specific. It is thought that murine TLR8 is either less functional or does 
recognize different structures than human TLR8 since Tlr7-/- mice do not respond to the TLR7 
and 8 agonist resiquimod or human TLR8 RNA ligands208,209. However, the human TLR8 
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agonist 3M-002 and polyT nucleotides were also recognized by murine TLR8210. It is thought 
that in contrast to human TLR8, murine TLR8 plays a negligible role in the recognition of 
ssRNA70. For instance, it is known that guanosine and uridine rich ssRNA oligonucleotides 
derived from human immunodeficiency virus–1 are recognized by murine TLR7 but human 
TLR8191. Interestingly, it has been reported that mice that lack TLR8 overexpress TLR7 and 
are hyperresponsive to TLR7 agonists. Tlr8-/- mice develop autoimmunity with splenomegaly, 
increased antibody titers and developed glomerulonephritis while Tlr7-/- Tlr8-/- double knock-
out mice did not show that phenotype211. Considering these species specific differences in TLR7 
and TLR8 function, we hypothesize that TLR8 compensates for the absence of TLR7 in human 
neutrophils and that TLR8 signaling in neutrophils early after infection would be important in 
the human immune response against L. major and that our results are also relevant for human 
disease. However, to confirm this hypothesis, further studies would be needed. 
                                                                                                                                                                                            
8.5 The Role of the Skin Commensals in Leishmaniasis 
It is known that LCL patients infected with L. braziliensis have a microbiome that is 
characterized by an abundance of Staphylococci in and around the lesion, which is distinct from 
the microbiome encountered on healthy skin. In L. major infected C57BL/6 mice a similar 
microbiome was detected212. Interestingly, the microbiome changed with disease severity and 
the biggest abundance of Staphylococci was found when the lesion was the largest. This 
dysbiotic microbiome could be transferred to naïve mice and was shown to have a deleterious 
effect on disease progression of subsequent L. major infection212. Furthermore, it has been 
reported that cutaneous commensals, notably Staphlyococcus epidermidis (S. epidermidis) 
promote lesion development in L. major infection in a MyD88 and therefore in a TLR signaling 
dependent manner213. S. epidermidis by itself does not induce skin inflammation and can even 
block TLR3 signaling in keratinocytes214. Thus, it is thought that the synergistic effect of S. 
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epidermidis and L. major leads to the disease phenotype observed in C57BL/6 mice. It would 
be possible that the absence of TLR7 would lead to an alteration of these mechanisms. Even 
though, TLR signaling does not have a big impact on physiological skin microbiome 
composition215, upon L. major infection the absence of TLR7 could lead to a different 
microbiome-dependent regulation of the disease phenotype observed. It would furthermore be 
of interest do determine whether there are differences in the microbiota composition in L. major 
infected C57BL/6 and Tlr7-/- mice, also because it is known that sand-fly gut microbes are 
transferred to the host during the sand fly bite 216. If so, it would be of interest to assess what 
the dynamics of these changes in microbiota compositions are and how they relate to the lesion 
development.  
Moreover, it would be interesting to assess whether there are changes in the microbiota 
composition between people that do or do not respond to antileishmanial drug treatment and 
whether the manipulation of the microbiota would have an effect on the therapeutic outcome. 
 
8.6 The Potential Role of Autophagy in Leishmaniasis 
Autophagy is a mechanism of eukaryotic cells that provides a mean for the elimination of 
unnecessary or dysfunctional intracellular structures or intracellular pathogens217. 
L. major infected macrophages undergo autophagy, which has been shown to restrict parasite 
replication in a endosomal TLR signaling dependent manner218. Chromatin decondensation in 
NET formation is autophagy and ROS dependent, at least when induced by PMA. In turn it is 
known that ROS is able to induce autophagy219-222. Also, neutrophil degranulation is dependent 
on autophagy223. In addition, autophagy has been shown to be involved in NET formation in 
sterile inflammation224.  
Here we have demonstrated that L. major and L. (V.) p. induce ROS production and NET 
formation in neutrophils. Moreover, we could show that L. (V.) p. induces neutrophil 
degranulation. In L. (V.) p. infection, the degree of the induction was dependent on the drug 
117 
 
susceptibility of the parasite. It can therefore be hypothesized that drug resistant L. (V.) p. lines 
would induce the autophagy machinery to a greater extent than drug susceptible L. (V.) p. lines. 
However, the exact role that autophagy plays in the interaction of l. (V.) p. and neutrophils 
would have to be elucidated in future studies. 
In L. major infection, the induction of neutrophil effector functions was dependent on TLR7 
signaling. It is possible, that in addition to the already established differences in neutrophil 
functions, the induction of autophagy would play an important role in neutrophil mediated 
parasite control since we have shown that Tlr7-/- mice have neutrophils that are more heavily 
infected and contain more parasites than their wild type counterparts. Previous studies have 
reported that Myd88-/- and Tlr3-/- Tlr7-/- Tlr9-/- triple knock-out macrophages are less capable to 
induce autophagy and are highly permissive for L. major replication218. It would be of great 
interest to determine if the same is the case in neutrophils, since autophagy has been shown to 
be essential for the main neutrophil effector functions 225. 
 
8.7 The Potential of Toll-like receptor 7 Agonists in Leishmaniasis 
Treatment 
Imiquimod is a synthetic imidazoquinolone that acts as TLR7 and TLR8 agonist. It is 
commercially available as 3.75% and 5%  topical cream. It is approved by Swissmedic for the 
use against condylomas, actinic keratosis and basal cell carcinoma226,227. However, there are 
several reports on a successful use of Imiquimod against cutaneous leishmaniasis. Imiquimod 
was shown to increase iNOS production in macrophages in vitro and to reduce lesion size in L. 
major infected BALB/c mice 228. In Peru, an endemic area of New World Leishmania spp., 
there is evidence that the combination therapy of meglumine antimoniate and topical 5% 
imiquimod against LCL leads to a faster lesion resolution than the therapy with meglumine 
antimony alone229-231. In Iran, an endemic area of Old World Leishmania spp., no benefit could 
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be shown in treatment success by combining antimony with imiquimod232. In Syria, topical 
imiquimod treatment led to a transient effect on lesion size within the first 2-4 weeks of 
treatment but had no effect on the final disease outcome233. Finally, in Kuwait it was reported 
that topical imiquimod treatment had no effect on disease outcome 234 
L. major is an Old World species, for which the efficacy of imiquimod in the clinical setting 
has not yet been sufficiently demonstrated. Considering that early TLR7 signaling in 
neutrophils is important for disease control, it is no surprise that the earlier studies did not show 
a beneficial effect of TLR7 signaling as we do here. Unfortunately, it is clinically not feasible 
to treat the patients during the first hours and days after a sand-fly bite because the disease will 
not have manifested itself yet. It would be, however, of great interest to determine whether it 
would be possible to select patients who have a high number of neutrophil present in the lesions 
and to see whether this specific patient population would respond to treatment with topical 
Imiquimod. Even though there is already a certain success in the treatment of leishmaniasis 
induced by New World species, such an approach could also improve patient care in the 
Americas as well.   
 
8.8 Concluding Remarks  
Leishmaniasis is a complex group of diseases against which there is an urgent need for the 
development of novel effective drugs. Until today the standard of care is often a therapy based 
on  antimony, a treatment modality first described 107 years ago235. Leishmania infection in 
immunology has been studied more intensively in the past decades, for instance when the 
Th1/Th2 paradigm in L. major infection was established. However, the critical role of 
neutrophils in immunity against Leishmania infection is just recently becoming apparent. This 
is not least due to a tendency to think of neutrophils as terminally differentiated killer cells with 
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a short life-span. In reality, the role of neutrophils in the shaping of immunity is much more 
complex. 
In this thesis, two specific roles of neutrophils in leishmaniasis were elucidated. First, the 
essential role of neutrophils in leishmaniasis pathogenesis is stressed as well as the importance 
to Toll-like receptor 7 signaling, notably in neutrophils, is demonstrated. Second, it is 
established that different lines of L. (V.) p, drug-resistant and drug-susceptible ones, interact 
with neutrophils differently and lead to differences in neutrophil activation. After the 
establishment of these findings the question of the clinical applicability naturally arises. Given 
the basic research character of this thesis, this question cannot be precisely answered yet. 
Nonetheless, given that there is already a Swissmedic, EMA and FDA approved topical TLR7 
agonist available, the determination of a relevant role of TLR7 in leishmaniasis potentially 
opens up the possibility of the development of new adapted treatment modalities. The 
importance of neutrophils in leishmaniasis generally suggests that these cells have to be more 
considered during the establishment of treatment modalities.  
In the end, the results of this thesis have to be integrated into the totality of the previous findings 
in the field of immunoparasitology, to strive for the advancement of patient care in neglected 
tropical disease.  
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12. List of Abbreviations 
30S ribosomal subunit 30 small ribosomal unit   
ACK buffer   Ammonium-Chloride-Potassium Buffer 
Acox2    Acyl-coenzyme a oxidase 2 
Acoxl    Acyl-coenzyme a oxidase like 
A.D.    Anno domini 
et al.    et alii/aliae 
Akr1c18   Aldo-keto reductase family 1 member c18 
Aldh3b2   Aldehyde dehydrogenase family 3 member b2 
Alox12e   Arachidonate 12-lipoxygenase, epidermal-type 
ATL    American tegumentery leishmaniasis 
AUC    Area under the curve 
B.C.    Before Christ 
BH    Benjamin Hurrell 
BM    Bone marrow 
BMS    Berenice Martínez-Salazar 
°C    °Celsius      
CCL2    C-C chemokine ligand 2 
CCL3    C-C chemokine ligand 3 
CCR2    C-C chemokine receptor 3 
CD4    Cluster of differentiation 4 
CD8    Cluster of differentiation 8 
CD11b   Cluster of differentiation 11b (Integrin α-M) 
CD11c    Cluster of differentiation 11c (Integrin α-X) 
CD14    Cluster of differentiation 14 
CD15    Cluster of differentiation 15 
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CD45 Cluster of differentiation 45 (Protein tyrosine phosphatase, 
receptor type, C) 
CD62L   Cluster of differentiation 62 ligand (L-selectin) 
CD66b   Cluster of differentiation 66b (CEACAM8) 
cDCs    Classical dendritic cells 
CIDEIM Centro Internacional de Entrenamiento e Investigaciones 
Médicas 
CL    Cutaneous leishmaniasis  
CpG    5'— Cytosine—phosphate—Guanine—3' 
CTL    Cytotoxic T-cell 
CXCL1   C-X-C chemokine ligand 1 
CXCL2   C-X-C chemokine ligand 2 
CXCL6 / GCP-2  C-X-C chemokine ligand 6 / Granulocyte chemotactic protein 2 
Cyp2b19   Cytochrome p450 2b19 
Cyp2g1   Cytochrome p450 2g1 
Cyp2j12   Cytochrome p450 2j12 
Cyp2j8   Cytochrome p450 2j8 
Cyp3a57   Cytochrome p450 3a57 
Cyp4j39   Cytochrome p450 4j39 
DAPI    4′,6-Diamidin-2-phenylindol 
DCs    Dendritic cells 
DCL    Diffuse cutaneous leishamniasis 
e.g.    Exempli gratia 
DHR123   Dihydrorhodamine 123 
DL    Disseminated leishmaniasis  
dLN    Draining lymph node 
DMEM   Dulbecco's Modified Eagle Medium 
DNA    Deoxyribonucleic acid 
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DNase    Desoxyribonuclease 
dsDNA   Double stranded deoxyribonucleic acid 
eGFP    Enhanced green fluorescent protein  
EMA    European Medicines Agency 
ERK1/2   Extracellular-signal Regulated Kinase 1/2 
F4/80 EGF-like module-containing mucin-like hormone receptor-like 
1 
Fa2h    Fatty acid 2-hydroxylase 
FACS    Fluorescence-activated cell sorting 
Far2    Fatty acyl- coenzyme a reductase 2 
FCS    Fetal calf serum 
FDA    Food and Drug Administration (United States) 
FRAC    Fluorescence recovery after conversion 
FTC / F.T.C   Fabienne Tacchini-Cottier 
G-418    Geneticin 
GCP-2    Granulocyte chemotactic protein 2 
G-CSF    Granulocyte-colony stimulating factor 
Gfi1    Growth Factor Independent 1 
GFP    Green fluorescent protein 
GO-analysis   Gene ontology analysis 
h    hours 
H-2    Histocompatibility-2 
HBSS    Hank's Balanced Salt Solution 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
Hephl1   Hephaestin-like 1 
HIV-1    Human immunodeficiency virus 1 
HLA    Human leukocyte antigen 
HLA-DR   Human leukocyte antigen – DR isotype 
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HSC    Hematopoietic stem cell     
Hsd17b2   Hydroxysteroid (17-beta) dehydrogenase 2 
Hsd3b6 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid 
delta-isomerase 6 
HSPC    Hematopoietic stem and progenitor cell 
i.d.    Intradermal 
i.e.     Id est 
IFN    Interferon 
IFN-β    Interferon-β  
IFN-γ    Interferon-γ 
IgA    Immunoglobulin A 
IgD    Immunoglobulin D 
IgE    Immunoglobulin E 
IgG    Immunoglobulin G 
IgM    Immunoglobulin M 
IL    Intralesional 
IL-1β    Interleukin 1 beta    
IL-2    Interleukin 2 
IL-4    Interleukin 4 
MIP-1β /CCL4  Macrophage inflammatory protein-1β / C-C motif   
    chemokine ligand 4 
IL-6    Interleukin 6 
IL-8    Interleukin 8 
IL-9    Interleukin 9 
IL-10    Interleukin 10 
IL-12    Interleukin 12  
IL-17     Interleukin 17 
IL-21    Interleukin 21 
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IL-22    Interleukin 22 
IM    Intramuscular 
iNOS    Inducible nitric oxide synthase 
IR    Ivo Regli 
IV    Intravenous 
kg    Kilogram 
KP    Katiuska Passelli 
L. amazonensis  Leishmania amazonensis 
L. brazilensis   Leishmania brazilensis 
L. chagasi   Leishmania chagasi 
LCF    Leihsmania chemotactic factor 
LCL    Localized cutaneous leishmaniasis 
LCMV   Lymphocytic choriomeningitis virus 
LDA    Limiting dilution assay 
L. donovani   Leishmania donovani 
L. evansi   Lutzomyia evansi 
L. infantum   Leishmania infantum 
L. major   Leishmania major 
L. major Sd   Leishmania major Seidman 
L. martiniquiensis  Leishmania matiniquiensis 
L. mexicana   Leishmania mexicana 
L. mexSWITCH   Leishmania mexicana photoswitchable 
L. longipalpis   Lutzomyia longipalpis 
L. olmeca   Lutzomyia olmeca 
L. panamensis   Lutzomyia panamensis 
LPG    Lipophosphoglycan 
LR    Leishmaniasis recidivans 
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L. tropica   Leishmania tropica 
L. vallesi   Lutzomyia vallesi 
L. (V.) p.   Leishmania (Viannia) panamensis 
L. whitmani / intermedia Lutzomyia whitmani / intermedia 
Ly6C    lymphocyte antigen 6 complex, locus C1 
Ly6G    Ly6g lymphocyte antigen 6 complex, locus G 
LysM    Lysin motif 
M199    Medium 199 
mAb    Monoclonal antibody 
MACS    Magnetic activated cell sorting 
MA    Meglumine antimoniate 
MAG    Maria Adelaida Gómes 
MAPK   Mitogen-Activated Protein Kinase Pathways 
MA-R    Meglumine antimoniate resistance 
MCL    Mucocutaneous leishmaniasis 
mg    Milligram 
MHC    Major Histocompatibility Complex 
MHC-II   Major Histocompatibility Complex, class II 
MIL    Miltefosine  
MIL-R    Miltefosine resistance 
mL    Milliliter 
µL    Microliter 
mm    Millimeter 
µM    Micromolar 
moDCs   Monocyte-derived dendritic cells 
MOI    Multiplicity of infection 
MPO    Myeloperoxidase   
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mRNA   Messenger ribonucleic acid 
MyD88   Myeloid differentiation primary response 88 
n    Sample size 
NADPH synthase / oxidases  Dihydronicotinamide-adenine dinucleotide phosphate synthase / 
oxidases      
NETs    Neutrophil extracellular traps 
NF-κB    Nuclear factor kappa-light-chain-enhancer of activated B cells 
NGS    Nancy Gore Saravia 
NIH/NIAID National Institutes of Health / National Institute of Allergy and 
Infectious Disease (United States) 
NIK    NF-KappaB Inducing Kinase 
NK-cell   Natural killer cell 
NKT-cell   Natural killer T cell 
NLRP3   Nucleotide-binding and oligomerization domain-like receptor 
    pyrin domain-containing 3 
Nm    Nanometer 
NNN medium   Novy-MacNeal-Nicolle medium 
NO    Nitric oxide 
NOD-like receptors  Nucleotide-binding oligomerization domain-like receptors 
NOX    NADPH oxidases 
NOX2    NADPH oxidase 2 
NW    New World species 
OF    Olga Fernandez  
OW    Old World species  
p28    Protein 28 
PAMP    Pathogen-associated molecular patterns 
P. alexandri   Phlebotomus alexandri 
P. argentipes   Phlebotomus argentipes 
P. ariasi   Phlebotomus ariasi 
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PBS    Phosphate-buffered saline 
PBMC    Peripheral Blood Mononuclear Cell 
P. chinensis   Phlebotomus chinensis 
pDCs    Plasmacytoid dendritic cells 
PDL1    Programmed death-ligand 1 
P. dubosqi   Phlebotomus dubosqi 
PFA    Paraformaldehyde 
PI3K    Phosphoinositide 3-kinase 
P. langeroni   Phlebotomus langeroni 
P. langeroni orientalis Phlebotomus langeroni orientalis 
P. longiductus   Phlebotomus longiductus 
PMA    Phorbol 12-myristate 13-acetate 
P. martini   Phlebotomus martini 
PMN    Polymorphonuclears (Neutrophils) 
P. neglectus   Phlebotomus neglectus 
P. papatasi   Phlebotomus papatasi 
P. perniciosus   Phlebotomus perniciosus 
PRR    Pattern recognition receptors 
PSG    Promastigote secretory gel 
P. seregentii   Phlebotomus seregentii 
PSN    Penicillin-Streptomycin-Neomycin 
P. syriacus   Phlebotomus syriacus 
PV    Parasitophorous vacuole 
Rdh1    Retinol dehydrogenase 1 
RNA    Ribonucleic acid 
ROS    Reactive oxygen species 
RPMI medium  Roswell Park Memorial Institute medium 
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SbV    Pentavalent antimony 
s.c.    subcutaneous 
Scd1    Stearoyl-Coenzyme A desaturase 1 
Scd3    Stearoyl-Coenzyme A desaturase 3 
Sdr16c5   Short chain dehydrogenase/reductase family 16C, member 5 
Sdr16c6   Short chain dehydrogenase/reductase family 16C, member 6 
Sdr42e1   Short chain dehydrogenase/reductase family 42E, member 1 
SNARF   Seminaphtharhodafluor 
spp.    Species 
SSG    Sodium Stibogluconate 
ssRNA   single stranded ribonucleic acid 
STAT-1   Signal transducer and activator of transcription 1 
STAT-4   Signal transducer and activator of transcription 4 
STAT-6   Signal transducer and activator of transcription 6 
TGF-β    Transforming growth factor β  
Th    T-helper 
Th1    T-helper1 
Th2    T-helper2 
Th9    T-helper9 
Th17    T-helper17 
Th22    T-helper22 
Tfh    T follicular helper cell 
TIR-domain   Toll/interleukin-1 receptor domain 
TLR    Toll-like receptor 
TLR1    Toll-like receptor 1 
TLR2    Toll-like receptor 2 
TLR3    Toll-like receptor 3 
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TLR4    Toll-like receptor 4 
TLR5    Toll-like receptor 5 
TLR6    Toll-like receptor 6 
TLR7    Toll-like receptor 7 
TLR8    Toll-like receptor 8 
TLR9    Toll-like receptor 9 
TLR10   Toll-like receptor10 
TLR11   Toll-like receptor 11 
TLR12   Toll-like receptor 12 
TLR13   Toll-like receptor 13 
TMRC    Tropical Medicine Research Centers 
TNF-α    Tumor necrosis factor-α  
TRAIL   Tumor-necrosis-factor-related-apoptosis-inducing-ligand 
Tregs    Regulatory T-cells 
TRIF    TIR-domain-containing adapter-inducing interferon-β 
UK    United Kingdom  
U.S.    United States 
USA    United States of America 
UV    Ultraviolet 
VL    Visceral leishmaniasis 
WHO    World Health Organization 
WHO-IRTC World Health Organization – Immunology Research and 
Trainings Center 
WT    Wild type 
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